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Purpose: The rapid distal falloff of a proton beam allows for sparing of normal 
tissues distal to the target. However proton beams that aim directly towards 
critical structures are avoided due to concerns of range uncertainties, such as CT 
number conversion and anatomy variations. We propose to eliminate range 
uncertainty and enable prostate treatment with a single anterior beam by 
detecting the proton’s range at the prostate-rectal interface and adaptively 
adjusting the range in vivo and in real-time. 
Materials and Methods:  A prototype device, consisting of an endorectal liquid 
scintillation detector and dual-inverted Lucite wedges for range compensation, 
was designed to test the feasibility and accuracy of the technique. Liquid 
scintillation filled volume was fitted with optical fiber and placed inside the rectum 
of an anthropomorphic pelvic phantom.  Photodiode-generated current signal 
was generated as a function of proton beam distal depth, and the spatial 
resolution of this technique was calculated by relating the variance in detecting 
proton spills to its maximum penetration depth.  The relative water-equivalent 
thickness of the wedges was measured in a water phantom and prospectively 
tested to determine the accuracy of range corrections.  Treatment simulation 
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studies were performed to test the potential dosimetric benefit in sparing the 
rectum. 
Results:  The spatial resolution of the detector in phantom measurement was 
0.5 mm.  The precision of the range correction was 0.04 mm.  The residual 
margin to ensure CTV coverage was 1.1 mm.  The composite distal margin for 
95% treatment confidence was 2.4 mm. Planning studies based on a previously 
estimated 2mm margin (90% treatment confidence) for 27 patients showed a 
rectal sparing up to 51% at 70 Gy and 57% at 40 Gy relative to IMRT and 
bilateral proton treatment.  
Conclusion:  We demonstrated the feasibility of our design. Use of this 
technique allows for proton treatment using a single anterior beam, significantly 
reducing the rectal dose. 
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Chapter 1: Introduction 
Prostate cancer is the most common malignant neoplasm for males in the 
North America with nearly 200,000 new diagnosis and over 25,000 mortalities in 
2009 (1).  Over the last century, prostate cancer treatment has evolved to allow 
curative treatment of the disease without severely affecting the patient’s quality of 
life.  Nonetheless, locally advanced and metastatic prostate cancer remains a 
potential lethal disease, and treatment of early stage disease can potentially 
recur adding a substantial monetary burden and reduction of the patient’s quality 
and duration of life.  Contemporary research aims to definitively treat disease and 
incur minimal treatment related side effects in a timely and fiscally responsible 
manner.  To this end, we will begin with a brief introduction to contemporary 
diagnosis and treatment of prostate cancer, the evolution of external beam 
therapy, the relation of toxicity with uncertainty and treatment margins, the 
resulting advancement of proton therapy, and culminate with our proposed 
treatment technique to maximize the advantages of proton therapy for treatment 
of the prostate. 
1.1 The evolution of external beam photon therapy for prostate cancer 
1.1.1 Detection, staging, and modality determination 
Early detection is the strongest factor for favorable disease prognosis (2).  
Prostate specific antigen (PSA) testing and digital rectal examination are 
recommended for screening prostate cancer in men over the age of 50.  If the 
absolute level of PSA detected in the blood or the PSA level relative to a patient’s 
2 
 
previous tests is abnormally high, multiple samples of prostatic tissue are 
biopsied from each geographic section of the prostate.  Tissue biopsy verifies the 
presence of the cancer, identifies the disease’s location for proper tumor staging, 
and provides cellular samples for disease prognosis.   
By examining the tissue sample from biopsy, the prostate cancer is 
graded according to the Gleason scoring system to indicate its level of 
aggressiveness and malignancy.  The system ranks the two most prominent 
cancer cell types according to their level of cell abnormality, and then adds the 
two numbers to generate the Gleason score.  After Gleason scoring, the 
disease’s stage is determined with the TNM system.  The TNM staging 
determines the progression of the disease within the organ of origin (T), the 
regional lymph nodes (N), and distant metastasis (M).  Prostate cancer is often 
confined to the prostatic capsule; however the malignancy may extend into the 
extra-prostatic tissue, seminal vesicles, pelvic lymph nodes, and may 
metastasize to skeleton or brain.  T2-weighted MRI and bone scans are often 
used to supplement CT pelvic scanning and biopsy results for proper tumor 
staging. 
Based on the previous three tests, patients are assigned a PSA level, 
Gleason score, and tumor stage. From these three factors the patients are 
stratified according to risk.  Low risk prostate cancer is defined as PSA levels of 
less than 10 ng/ml, Gleason scores less than 7, and T1 or T2 stage disease on 
only one side of the prostate.  Intermediate risk cancers have slightly higher PSA 
levels (10-20 ng/ml) or a Gleason score of 7.  Seminal vesicle invasion, a 
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Gleason score greater than 7, or a PSA level greater than 20 ml/ng place the 
disease within the high risk stratification.   
Clinicians consider the disease’s risk classification, the patient’s health, 
and treatment side effects when choosing their patient’s treatment modality.  
There are several effective treatment options for low-risk locally confined disease 
of the prostate including brachytherapy and radical prostatectomy. Both 
approaches offer a safe treatment option with an excellent chance of local tumor 
control.  Both of these modalities have the potential to spare small critical 
structures that are related to the patient’s urinary and reproductive function such 
as the penile bulb, neurovascular bundle, and urethra.  However, both carry the 
risk of leaving residual tumor untreated, the risk of infection, and potentially delay 
the patient’s recovery.  Additionally, tumor mis-staging is not uncommon, and 
locally confined treatments carry the risk of mistreatment of extraprostatic 
disease and risk subsequent disease recurrence. For these reasons, external 
beam radiation therapy is often used to treat low-risk disease and is the modality 
of choice for intermediate and high-risk diseases.  .  HT is often used as an 
adjunct to external beam radiation therapy to ablate the tumor volume 
(neoadjuvant hormone therapy, NAD), relieve the patient of disease-related 
symptoms, reduce the overall treatment volume thus sparing normal tissue, and 
potentially reduce the overall stage of the disease (3).  Several studies even 
suggest the local control and survival benefits of their combined treatment are 
much greater than either treatment alone (4, 5).  The exact mechanism for the 
observed supra-additive effect of combination radiotherapy and hormone therapy 
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is a topic of debate, however some in vitro evidence suggests that hormone 
therapy may potentiate cell death following curative level of radiation dose by 
enhancing the cellular apoptotic pathway (6).  Our in-house study demonstrated 
the dosimetric advantages of post-NAD treatment planning and the risk of 
treating based on pre-NAD treatment images (Figure 1).   
 
Figure 1: NAD-induced target volume reduction and the importance of 
treatment planning after HT. 
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The top left of Figure 1 illustrates the pre-NAD plan on the pre-NAD 
anatomy.  The top right shows the same plan applied to the anatomy after 108 
days of NAD resulting in increased bladder dose with little change of the rectal 
and bladder volumes or the rectal dose.    The bottom left illustrates the post-
NAD plan on the post-NAD anatomy.  The bottom right shows the post-NAD 
coverage of the pre-NAD tumor bed.  Areas of both the prostate and SV were not 
treated to the full prescription dose. Pre-NAD planning does not ensure coverage 
despite its large treatment volume. 
1.1.2 Dose-escalated radiotherapy, toxicity, and treatment margins 
The escalation of dose to target organs was one of the first and most 
critical steps to definitive radiotherapy of advanced prostate carcinoma (7).  Early 
retrospective studies of dose escalation (8, 9) without the benefit of conformal 
technologies indicated that escalated radiation dose may improve survival in 
advanced cases.  The early Phase I single institution clinical trials of Hanks et al 
(10) and Zelefsky et al (11) showed an increased biochemical freedom from 
relapse (BNED) among high-risk patients.  The Phase III clinical trial by Pollack 
et al. (12) showed an improvement in freedom from failure (FFF) within the dose 
escalation arm, however this particular study was not sufficiently powered to 
demonstrate efficacy of dose escalation in low-risk patients.  A more recent study 
demonstrated escalation to 79.2 Gy from 70.2 Gy, halved the risk of biochemical 
recurrence in 393 patients with disease staged T1b-T2b and PSA levels less 
than 15ng/ml (80.4% vs. 61.4% BNED)(13).  These studies demonstrated the 
benefit of treating with higher dose, even in low-risk disease, to reduce disease 
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recurrence.  Survival advantage was difficult to establish in short term studies 
with low-risk patient population. However, local control of prostatic disease has 
shown to reduce metastatic dissemination(14) and subsequent metastasis-free 
survival(15, 16).   
Unfortunately, high dose treatment arms in early non-conformal dose 
escalation studies resulted in severe rectal complications (17-19).  Rectal late 
effects included many factors including bleeding, incontinence, diarrhea, oily 
discharge, colic, and increased voiding frequency.  Non-IMRT dose escalation 
trials demonstrated an approximate 2-fold increase in Grade 2 and 3 late rectal 
toxicity including two trials with greater than 26% incidence (11-13, 20).  A few of 
the early trials found correlation of dose with late bladder toxicity (18, 21, 22); 
however, most of the following clinical trials found similar bladder toxicity in 
escalated and non-escalated treatment arms (12, 13, 23).   
The efficacy of dose escalation and the corresponding risk of morbidity for 
all disease sites was the impetus for the development of modern conformal 
radiotherapy.  While two dimensional computer calculations and dose models 
were available in the 1960’s, the development of computed tomography (CT) and 
the introduction of the beam’s eye view (BEV) concept in the late 1970’s and 
early 1980’s let to the development of the first three-dimensional treatment 
planning system (24).  3DCRT treatment included physical collimation with 
cerrobend or lead blocks attached to the head of the gantry, new plan evaluation 
tools such as the dose volume histogram (DVH), and new biological effect 
models such as tumor control probability (TCP) and normal tissue complication 
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probability (NTCP).  These advances improved the therapeutic ratio and allowed, 
to some extent, dose escalation without severe adverse effects to surrounding 
critical structures.   
The emergence of intensity modulated radiation therapy (IMRT) began 
with the development of the multi-leaf collimator (MLC).  With the MLC, 
collimation could be dynamically changed or segmented to create non-uniform 
beam intensities.  New software developments enabled treatment-planning 
systems to optimize the beam intensity according to desired dose distribution 
input by the user.  These advances led to greater conformation of the treatment 
field to the tumor (25) and further reduced rectal and bladder dose during therapy 
(26, 27).  The highly conformal dose distributions achievable with an IMRT 
system made treatment planning highly sensitive to target position uncertainties 
(28-30), which led to a need to characterize, immobilize, and localize the target 
organs during radiotherapy. 
Conformal radiotherapy technologies required a new set of nomenclature 
to describe volume-based treatment.  ICRU Report 29 was published in 1978, 
defining a target volume that included gross tumor, movements, variations, and 
uncertainties in treatment (31).  The advent of CT simulation and computer 
technology prompted ICRU Report 50, which split the target into 3 parts, the GTV, 
CTV, and PTV (32).  The GTV included the gross tumor volume, the clinical 
target volume (CTV) included the GTV plus uncertainty in microscopic spread, 
and the planning target volume (PTV) included the CTV plus geometric (patient 
movement and setup) uncertainties.  ICRU Report 62 was published in 1999 as a 
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supplement to ICRU Report 50(33).  This report refined the definition of the PTV 
by segregating the  single PTV expansion into two expansions of the CTV, one 
for organ motion and one for patient set-up and other uncertainties  (34). 
1.1.3 Treatment uncertainty and its management 
Although the ICRU defined the nomenclature used in radiotherapy, the 
clinical and research community was still responsible for determining the 
uncertainty values and the corresponding treatment margins to apply.  The three 
primary sources of uncertainty in photon radiotherapy are target volume 
delineation, setup error, and organ motion.  Since these sources are independent, 
the total target uncertainty is approximately the square root of the quadratic sum 
of each source.  The composite treatment uncertainty is used to calculate the 
proper treatment margins to ensure coverage of the treatment target with a 
specified statistical confidence, usually 95%.  Since the relative amount of dose 
the normal tissues receive during treatment and the confidence of target 
coverage are directly related to the size of the treatment margins utilized,  much 
of contemporary medical physics research is aimed at the reduction of treatment 
uncertainty to improve the therapeutic ratio of treatment (35). 
Treatment uncertainty begins with delineation of the disease volume.   
Several factors contribute to the uncertainty in target delineation beginning with 
the limitations of the imaging device (36).  Many imaging modalities have limited 
spatial resolution particularly in the direction perpendicular to the slice plane.  
Anatomic information within the coarse voxel is averaged leading to a partial 
volume effect.  The process of target delineation, i.e. contouring, is also a major 
9 
 
source of uncertainty.  Repeat contouring of a single physician or contouring 
differences between physicians can greatly affect both treatment planning and 
dose reporting in radiotherapy.  The most common ways to manage target 
delineation uncertainty is with the use of functional imaging (PET, MRI, etc.) co-
registered and rendered into CT for improved target definition or the use of 
automated delineation, or “segmentation” tools, to improve the consistency of 
target definition. 
Setup uncertainty involves registration of the external surface of the 
patient, the room, and the treatment couch.  Patient set-up is achieved with the 
use of external immobilization for proper registration of treatment with the 
patient’s external anatomy and for reduction of the patient’s movement during the 
treatment.  Some of the more common external immobilization devices include 
the body cradle, thermoplastic shells, knee wedge, and Vac-Lok bag (37-40).  
These devices are made of foam or plastics that tightly conform to the patient’s 
body, immobilizing them during treatment. 
Even with careful immobilization and alignment of the patient, significant 
changes occur because of the non-rigidity of anatomy, bowel gas movement, 
feces, and the variable filling of the bladder (41-43).  Some institutions attempt to 
control the fullness or emptiness of the rectum during treatment, and most 
institutions treat with a full bladder to improve dosimetry of the bladder wall and 
the small bowel and to potentially immobilize the bladder.  Although rectal and 
bladder filling induced treatment uncertainties are less when treating patients in 
the prone position, most institutions elect to treat in the supine position to 
10 
 
minimize treatment uncertainty caused by respiratory motion (44, 45).  Organ 
motion is categorized into motions that occur between fractions, interfractional 
motion, and those that occur during the fraction, intrafractional motion.  Previous 
studies indicate that interfractional motion is the greater of the two types of 
motion (45), which is fortunate because it is simpler to manage.   
One method for the management of interfractional motion is image-guided 
target localization.  In traditional clinical practice, patient positions are adjusted 
based on periodic portal imaging.  This localization device consists of a flat-panel 
detector attached to the gantry of the linear accelerator, allowing for convenient 
megavoltage x-ray imaging of the patient in the treatment position.  Many 
corrective and adaptive procedures have been developed for improving 
treatment quality including offline correction to the patient’s bony anatomy, online 
correction of the patient in conjunction with implanted fiducials, and the 
monitoring of motion for future planning adaptation.  The disadvantages of the 
EPID include poor soft tissue contrast and the lack of proper three dimensional 
tissue density information needed for the recalculation of dose.  Because of poor 
soft tissue contrast of kilo- or mega-voltage x-rays, bony landmarks are generally 
used for patient setup.  However, bony landmarks do not accurately represent 
the positions and shapes of the target and normal tissues.  Implanted radio-
opaque markers may improve registration of the treatment to soft tissue targets 
such as the prostate, however, they may exhibit migration or positional instability 
when organ shape variation occurs (46, 47). For these reasons, many 
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manufacturers have moved to more advanced on-board technologies that 
address these limitations (48). 
Current clinical practice for prostate radiotherapy also includes the use of 
trans-abdominal ultrasound systems (49-51).    The ultrasound system sends and 
receives sound waves, which are used to identify the tissue interfaces between 
organs for daily target localization.  However, inter- and intra-user variability in 
the operation of ultrasound devices (52), the inherently poor quality of ultrasound 
images, and anatomic distortions resulting from the pressure on the abdomen 
(50) reduce the effectiveness of these devices.  
An alternative to target localization techniques are internal immobilization 
devices. These manage both interfractional and intrafractional motion by 
stabilizing the volume of the rectum and bladder.  There are a wide variety of 
internal immobilization devices for the pelvic anatomy, yet the most common are 
catheters, enemas, and balloons.  Catheters are used to control the volume of 
the bladder, ensuring that the prostate receives the prescribed dose and that the 
bladder and small bowel remain out of the high dose region.  Rectal balloons and 
enemas are used to control rectal filling.  An enema empties the rectum of feces 
and reduces the generation of gas in the upper bowel.  Rectal balloons help 
maintain a constant rectal volume during treatment in addition to pushing the 
lateral and posterior rectal walls away from the radiation.  These may help in 
controlling internal soft tissue variations(53-57),  however, residual target motion 
may still compromise a patient’s daily treatment fraction ,. 
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The most precise forms of contemporary target localization are those that 
utilize on-board kilovoltage volumetric imaging for precise daily image-guide set-
up such as “cone-beam” CT (58) and the “CT-on-Rails” (59).  Cone-beam 
technology utilizes a point x-ray source and a flat panel detector to reconstruct 
three-dimensional objects.  The “CT-on-Rails” system is a CT-linear accelerator 
combination treatment system that allows for daily diagnostic quality CT tumor 
localization without removing the patient from the treatment couch.  Both allow 
for daily target registration with millimeter precision, however, both methods are 
limited by delineation uncertainty, target deformation, and intrafractional 
anatomic variation. 
Our in-house studies of intrafractional prostate motion addressed the 
limitations of on-board CT imaging for daily correction of treatment uncertainties 
(60, 61).   We observed anterior and inferior displacement of the target organs 
strongly correlated with gaseous build-up of the rectum (P<0.001) in a cohort of 
46 prostate cancer patients (Figure 2).  The top of figure 2 illustrated an axial 
slice of the patient’s anatomy near the base of the prostate and the proximal 
seminal vesicles.  The arrows indicated the deformation of the patient’s pelvic 
anatomy to the image of the patient’s post-fraction CT (bottom).  The rectum 
expanded shifting prostate and proximal SV anteriorely and superiorly.  The 
mean time interval in between CT image acquisitions was 21 minutes.  One 
standard deviation of anterior displacement was 2.9 mm and 4.1 mm for the 
prostate and seminal vesicles respectively.  One standard deviation of intra-user 
contouring uncertainty was 0.9 and 1.3 mm anteriorely for the prostate and SV 
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and 1.4 and 1.7 mm inferiorely for the prostate and SV respectively.  These 
results suggested that our current margins do not completely correct for 
variations of the target during treatment and warranted further investigation. 
 
Figure 2: Intrafractional gaseous build-up in the rectum. 
To test the sensitivity of prostate IMRT to intrafractional variations, we 
simulated patient treatment on a CT obtained before the patient’s daily treatment 
fraction and applied this plan to their post-fraction anatomy.  We used a three-
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millimeter internal target volume, ITV, based on the results in our first study and 
approximation of our current clinical margins that address intrafractional organ 
motion.  Of 46 patients treated to 75.6 Gy, 3 patient’s prostates and 8 patient’s 
seminal vesicles were not covered at the 70 Gy isodose level (92.5% of 
prescription).  An example is shown in Figure 3.  The top of figure 3 illustrates the 
deformation field of the pre-fraction anatomy onto the post-fraction anatomy in 
the pelvic.  Gas migration along with bladder filling has pushed the target organs 
(PTV (blue), prostate (red), SV (orange)) anterior and superior to the 60 Gy 
isodose and deformed the shape of the target. 
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Figure 3:  Intrafractional prostate deformation and resultant treatment 
fraction. 
This study addressed the theoretical limits of what sophisticated on-board 
imaging can achieve if used daily before a treatment fraction.  Thus, the 
treatment margins and resulting therapeutic ratio of external beam radiotherapy 
for the prostate has approached a limit of approximately 3 mm.  Further 
improvement would be extremely difficult without radically improving the way the 
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prostate is treated.  These limitations have contributed to the development of 
proton facilities world-wide to further spare normal tissue and improve treatment 
effectiveness. 
1.1.4 Summary: The evolution of external beam photon therapy for 
prostate cancer 
 Prostate cancer patients and their physicians may elect numerous ways to 
treat prostate cancer, but external beam photon therapy has evolved as a 
favorable choice for low risk disease and the preferred choice for intermediate 
and high risk diseases when combined with neoadjuvant or concomitant 
hormone therapy.  Early dose escalation trials with 3DCRT led to unacceptable 
morbidities of the rectum and bladder.  These treatment morbidities led to the 
development of IMRT.  Modern conformal radiotherapy was more sensitive to 
treatment uncertainty and required new treatment margin definitions.  Additional 
technologies were developed to reduce target delineation, patient set-up, and 
organ motion uncertainties and therefore reduce margins and improve the 
therapeutic ratio of treatment.  These technologies included multi-modality 
imaging, segmentation tools, external immobilization devices, two dimensional 
image-guided localization, internal immobilization devices, and volumetric image-
guided target localization.  Even with daily image-guided target localization, 
residual uncertainties limited further reduction of margins and improvement of 
external photon beam treatment of prostate cancer.  These limitations 
contributed to the development of proton facilities world-wide to potentially further 
spare normal tissue and improve treatment effectiveness. 
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1.2 The development of modern proton therapy for prostate cancer 
1.2.1 Advantage of protons to spare normal tissues 
The reduction of inter-fractional motion and set-up uncertainty in external 
beam photon radiotherapy has led to the reduction of treatment margins, the 
ability to escalate target dose for improved local control of disease, and the 
reduction of normal tissue doses adjacent to the target organs.  However, the 
therapeutic ratio of external beam photon therapy is ultimately limited by the 
physics of photon attenuation as the photon beam enters, irradiates, and exits 
the patient’s body.  The depth dose of photons rises abruptly upon entering the 
patient and reaches a maximum when the number of charged particles entering a 
volume is equivalent to those ionized that exit the volume, a condition known as 
electronic equilibrium.  This depth can be as great as three centimeters in the 
case of 18 MV photons.  Photons attenuate en route to the target volume, 
resulting in considerably less absorbed dose inside the target.  Photons then 
pass though the distal portion of the patients anatomy relatively unimpeded, 
resulting in further irradiation of normal tissues as they exit the patient.  
Therefore, clinicians utilize multiple beams to spread entrance and exit photon 
dose over a large volume of normal tissue. Clinicians assume that these tissues 
can tolerate a moderate dose and patients will experience few or no adverse 
effects as a result of their treatment. 
In the 1940’s, Robert Wilson suggested that proton therapy dose 
distribution might result in superior treatment for cancer patients (62).  Therapy 
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with charged particles can circumvent some of the limitations of photon 
radiotherapy treatment.  Protons deliver the majority of their dose at the Bragg 
peak near the distal end of the beams range.  The normal tissue dose is reduced 
proximal to the target and eliminated just millimeters distal to the target. 
Therefore, proton therapy offers a theoretical advantage over photon therapy for 
reducing the irradiated volume of non-target tissues.  Additionally, the distal falloff 
of a proton beam is considerably sharper than the lateral penumbra of a photon 
beam, theoretically allowing for rapid dose falloff near adjacent critical structures 
(63). 
1.2.2 Proton delivery technology 
Passively scattered proton delivery relies on many technologies to deliver 
conformal treatment to the entire tumor volume.  The first technology is the 
scattering foils which turn a proton pencil beam into a flat field of uniform fluence 
at the surface of the target (Figure 4).  The first scattering foil spreads the beam 
resulting in a wide field with Gaussian fluence.  The second scattering foil flattens 
the fluence by scattering protons near the center of the field.  The distance 
between the first and second foil, second foil and patient, and the lateral scatter 
of the protons results in a beam of uniform fluence for a specified source to 
surface distance (SSD). 
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Figure 4: Dual scatter design to generate a large flat field, (64) 
The second technology is the range modulator.  The range modulator is a 
rotating wheel with varying thickness (steps) of attenuating material that 
degrades the initial proton energy to cover the target uniformly from its proximal 
to distal end (Figure 5).  The relative weighting of each of the Bragg peaks is 
computed to generate a uniform treatment of a tumor volume.  The sum of these 
degraded peaks is termed, the spread out Bragg peak (SOBP).  The proper 
SOBP width is achieved by gating the proton beam with a specific window of 
thickness on the rotating wheel.  The same range modulation can be achieved 
with spot-scanning systems by directly varying the initial energy of the beam and 
weighting these beams appropriately. 
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Figure 5: Range modulator wheel 
The third technology that allows for conformal proton delivery is range 
compensation.  Range compensation corrects for the shape of the patients 
surface, tissue inhomogeneites in the beam’s path, and the shape of the distal 
target volume.  The compensator achieves conformal treatment by degrading the 
beam along each ray path to precisely match the distal end of the target volume 
(Figure 6).  In the absence of heterogeneity along the proton beam-path, the 
compensator shape will closely match the shape of the distal edge of the target.  
The compensator in figure 5 is much thinner in the area upstream from the high-
density structure to correct for its relatively high radiological thickness. 
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Figure 6: Range compensation for conforming a proton beam to the distal 
target, (65) 
 
1.2.3 Proton range uncertainty and its management 
Since protons deliver their energy over a relatively short area and their 
range is highly sensitive to variation in density and proton stopping power along 
the path of the beam, management of all set-up and organ motion uncertainties 
are critically important.  One type of range uncertainty is caused by variation of 
tissue heterogeneities, usually air or bone, in the direction perpendicular to the 
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beam path.  Since the range compensator is unique for each beamlet, variation 
in the radiological pathlength to the distal edge of the target will result in a 
variation in the proton range and either a loss of dose in the target or 
unnecessary dose to distal normal tissues.  
In the case of prostate treatment, femur and femoral head rotations have 
typically been neglected in positioning studies for prostate cancer patients 
because their impact on patient dosimetry is minimal for photon therapy unless 
they result in geometric translation of the pelvis or internal pelvic organs.  
However, femur and femoral head (FH) rotations may be critical to treatment 
uncertainties in prostate proton radiotherapy. We performed an in-house study to 
investigate the variation of the femur and femoral heads during treatment and its 
effect on bilateral proton treatment (discussed fully in Appendix B).  The range 
defined by the Bragg peak in proton therapy is roughly proportional to the 
radiological path length in the beam path. Range uncertainties in the bilateral 
proton therapy of the prostate can potentially compromise the distal coverage of 
the target. In addition, dense bony structures, such as the femur and FH, in the 
beam path can also cause uncertainties in dose distributions because the Bragg 
peak becomes degraded (66).  This degradation, in turn, affects the final dose 
distribution (67).  Hence, depending on the type of immobilization device used, 
changes in daily patient setup during the course of proton radiotherapy could 
introduce varying amounts of bone in the treatment field due to FH rotation.   
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Figure 7: Smearing of a range compensator (68) 
It should be noted that in proton radiotherapy “smearing” (68, 69) is 
typically applied to the range compensator design in an attempt to resolve the 
range uncertainty (Figure 7).  Range compensators are used in proton 
radiotherapy to conform the distal edge of each beam to the target while 
accounting for the heterogeneities along each beam path.  With the appropriate 
application of smearing in the design of each compensator, the changes in 
radiological path length resulting from tissue motion should not lead to insufficient 
proton penetration, thus maintaining distal coverage of the target. However, 
compensator smearing is usually two-dimensional and orthogonal to the beam 
path, so a significant anatomical rotation may not be fully compensated. To 
illustrate this, we designed a single lateral proton beam plan with the greatest 
rotational misalignment found in our study (Fig. 8). Figure 8 (a) shows the 
reference CT image set and plan in colorwash (top) and linear (bottom) isodose 
lines.  Figure 8 (b) shows the reference plan recalculated on a daily CT image set 
in the Eclipse treatment planning system (Varian Medical Systems, Palo Alto, 
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CA).  We found that the typical 6.6-mm smearing in our routine proton plan for 
prostate treatment did not preserve the dose coverage in this case: The dose 
coverage for the prostate dropped from 75.6 Gy (prescription dose) to only 60 Gy.  
While a single fraction of treatment with the misaligned FH may not have clinical 
impact, a large systematic error in FH position would present a problem.  It is 
worth mentioning that the dosimetric impact of FH/femur position in proton 
therapy cannot be resolved by simply using image-guided setup techniques. 
Range uncertainties due to daily radiological path length variations require the 
design of better immobilization devices or range verification to ensure accurate 
delivery of prescription dose to targets. 
a) b)
 
Figure 8: Changes in dose distribution after a 20-degree femoral head 
rotation. 
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Another type of range uncertainty is caused by uncertainties in 
determining the relative stopping power ratios for various tissue from CT 
Hounsfield units (HU).  CT reconstructs the photon linear attenuation coefficient 
at each voxel within the patient.  The measured HU is then used to determine the 
electron density of the material.    Even in homogeneous material, variation in the 
HU can be 1 to 2% (70) and up to 3% depending on the location within the 
phantom (Moyers 1993).  The proton stopping power is then approximated from 
the estimated electron density.  This approximation is usually accomplished with 
a stoichiometric calibration method with tissue equivalent materials described by 
Schneider et al (71).  Even with rigorous calibration of CT to approximate proton 
stopping power, uncertainty in the calculation of the proton’s range persists.  If 
the stopping power ratio is questionable or the water-equivalent path length 
varies, the proton beam may not stop at where you think when designing the 
proton treatment.  Thus, we apply a generous margin, 3 and one half percent of 
the protons total range plus 3 millimeters, to account for the uncertainty in range 
calculation from CT Hounsfield units (69)(Figure 9). 
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Figure 9: Distal margin applied to a lateral proton beam 
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The previous sections discussed the advantages of proton treatment and 
the challenges unique to the modality, i.e. range uncertainty.  Unfortunately, the 
primary tool of protons to maximally spare adjacent critical structures, the abrupt 
distal fall-off, cannot be easily utilized in most clinical conditions, such as in the 
sparing of the rectum in prostate cancer treatment. This is because the range 
uncertainties in proton therapy require large treatment margins and thus limit the 
normal tissue sparing capabilities for organs just adjacent to the target. The 
range uncertainties are caused by uncertainties in determining the relative 
stopping power ratios for living tissues from CT Hounsfield units or the daily 
organ variations.  The variation of physical depth from variation of the pelvic 
anatomy is demonstrated in Figure 10.Figure 10 illustrates interfractional prostate 
motion caused by bladder filling in a patient with endorectal balloon 
immobilization.  Even with the balloon the distance from the anterior rectal wall to 
the skin surface at the mid-sagittal slice has increased by more than 1 cm.  The 
prostate has shifted more than 5 millimeters posteriorely. 
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Figure 10: Anatomic variation in the depth to the anterior rectal wall 
12.01 cm 
13.06 cm 
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 If the proton beam is directly pointing towards the rectum from the anterior 
direction, the range uncertainty of the Bragg peak can either over-irradiate the 
rectum or miss the posterior portion of the prostate target (adequate dosing of 
the peripheral zone is important in prostate treatment).  Therefore, all current 
proton treatment techniques for prostate cancer use a lateral beam arrangement 
method,(13, 72, 73) which do not fully take the advantage of the sharp fall-off of 
proton beams. Proton therapy for prostate cancer using an anterior field is 
achievable only if one can accurately control the location of the sharp distal fall-
off, as illustrated in Figure 11.  The proposed anterior proton beam treatment 
would utilize the sharp distal fall-off of the proton beam to maximize sparing of 
the rectum during radiotherapy. 
 
Figure 11: Prostate treatment using an anterior proton field 
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1.2.4 Summary: The development of modern proton therapy for 
prostate cancer 
Protons deliver sub-maximal dose proximal to the target, maximal dose at 
treatment depth, and nearly no dose distal to the target. Therefore, protons have 
a theoretical advantage over treatment with photons.  Conformal proton 
treatment is achieved with the use of dual scattering foils to generate a flat 
fluence profile, range modulator wheel to treat to a volume, and range 
compensator to conform a beam to the distal edge of the target organs.  The 
proton’s range is extremely sensitive to the stopping power of tissues in the path 
of the beam.  The first source of range uncertainty is variation of heterogeneous 
material such as bone and air in the direction perpendicular to the beam path.  
Therefore the range compensator designed so that distal coverage of the target 
organs is maintained when tissue heterogeneities vary.  However, rotations of 
highly dense objects, such as the femurs in the treatment of bilateral prostate 
treatment, may increase the radiological pathlength beyond those observed at 
reference CT and generate mis-coverage in the target organs.  The second 
source of uncertainty is determination of proton stopping power from CT 
Hounsfield units.  A generous distal margin is applied to the target organs to 
ensure coverage.  The distal margin in conjunction with anatomic variation in the 
path of the beam prohibits clinicians from aiming proton beams directly at critical 
organs.  In the case of the prostate, an anterior proton beam could treat the 
target while using its abrupt distal fall-off to maximally spare the rectum.  
However, without accurate control of the proton’s range, treatment with the 
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anterior beam either risks loss of treatment in the distal prostate or over exposure 
of the rectum. 
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Chapter 2: Hypothesis and Specific Aims 
 This chapter will begin with the purpose of the dissertation, state our 
hypothesis, state our specific aims to test our hypothesis, and conclude with the 
anticipated impact of the dissertation. 
2.1 Purpose 
The long-term objective of research in radiation oncology is the 
improvement of patient treatment, both in terms of biological outcome and quality 
of life.  The proposed project has the potential to achieve both, for prostate 
cancer patients.  The objective of this research is to reduce rectal dose delivered 
to patients receiving proton radiotherapy of the prostate, while providing dose 
enhancement to the prostate target.  To achieve this goal, we will develop a 
novel system to reduce proton range uncertainty and enable the treatment of 
prostate cancer with an anterior proton beam arrangement. The proposed 
system uses a liquid scintillation filled rectal balloon to detect the distal edge of 
an anterior proton beam in vivo. The liquid-filled rectal balloon has a dual 
function. The first function is to act as an internal immobilization device for the 
rectum and the prostate. Liquid-filled rectal balloon will proactively stabilize both 
the rectum and the prostate. In addition, measurement of real-time scintillation 
light produced by the radiation interacting with the scintillation fluid reaching the 
rectum, will allow for continuous adjustment of the proton beam’s fall-off position 
with a computerized range shifter.  A schematic of the system design is shown in 
Figure 12. Real-time range detection and adaptively adjusting the proton 
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penetration depth from the anterior beam allows for a minimal distal margin, 
resulting in superior rectal sparing over conventional bilateral proton treatment or 
IMRT. 
A computerized
sliding range shifter
Proton
Beam
Fiber optic cable
Controller Box
Photodectector
Rectal balloon filled with liquid 
scintillation radiation detector 
Stepping motor
 
Figure 12: The in vivo proton beam positioning system 
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2.2 Hypothesis  
The use of in vivo proton beam detection within a rectal balloon and dynamic 
range modulation of an anterior proton beam will enable the use of a reduced 
distal margin, reducing the mean rectal dose by 20% over conventional bilateral 
proton treatment and IMRT. 
2.3 Specific Aims 
1. Develop an in vivo proton beam detection device located within a rectal 
balloon. 
Working hypothesis: An in vivo proton beam detection device located within a 
rectal balloon can detect the distal fall-off of a proton beam within 2 mm (95% 
confidence interval). 
2. Develop a computerized external proton beam range shifter to modulate 
proton beam energy/range. 
Working hypothesis: An external proton beam range shifter can modulate proton 
beam energy/range and localize the distal fall-off of a single anterior proton beam 
to the anterior rectal wall within 2 mm (95% confidence interval). 
3. Determine dosimetric benefit of utilizing the in vivo proton beam 
detection device and external proton beam range shifter,  
Working hypothesis: Using the measured precision of the in vivo proton beam 
detection device and external proton beam range shifter, the reduced margin 
planning treatment strategies reduce mean rectal dose by 20% over conventional 
bilateral proton and IMRT photon therapies. 
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2.4 Impact  
The proposed in vivo patient positioning system will have an immediate 
impact on the treatment quality of current and future prostate cancer patients.  
The ability to spare extra volume of rectum during radiation treatment will 
substantially improve the patients’ quality of life by reducing the incidence of 
radiation induced rectal toxicity and potentially secondary malignancies.  The 
advantages of rectal sparing on patient rectal toxicity and quality of life were 
demonstrated with widespread adoption of IMRT over 3D-conformal photon 
therapy (26, 27, 74). Several studies have quantified the relation dose-volume in 
the rectum with probability of rectal toxicity and suggest that rectal toxicity is 
directly tied to volume of the rectum receiving near prescription doses (53, 75-
78)).  Conventional bilateral proton treatment provides little improvement over 
IMRT, with the exception in the low dose region. Our proposed anterior beam 
treatment substantially improves rectal sparing over both modalities. This 
treatment strategy takes advantage of the abrupt distal fall-off a proton beam.  By 
detecting the distal falloff of a proton beam in vivo, we eliminate the need for the 
large distal margin and allow treatment with a highly conformal anterior proton 
beam.  The system may also benefit future spot scanning and intensity-
modulated proton therapy techniques, which provide further dose conformality to 
reduce normal tissue toxicity.  
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Chapter 3: Detection of an anterior proton beam for range 
determination 
3.1 Introduction 
Specific Aim 1: Develop an in vivo proton beam detection device located 
within a rectal balloon. 
Working hypothesis: An in vivo proton beam detection device located within a 
rectal balloon can detect the distal fall-off of a proton beam within 2 mm (95% 
confidence interval). 
 The first part of our detection system includes the endorectal balloon, 
scintillating solution, and photon detection system.  With this system, if the 
anterior proton beam over-shoots through the prostate, a portion of the proton 
energy will be absorbed by the liquid scintillator, which tightly wraps around the 
anterior rectal wall and produces light emission within the scintillation liquid. The 
light produced can be captured and transmitted to the photo detector using a 
fiber optic light guide. The emitted light will be transmitted to a photodetector, at 
which the light signal will be converted into electric signal. If the proton beam 
range is too short, the proton beam will not penetrate the rectal balloon, 
therefore, there will be no signal detected by the system.  
 This chapter will begin with a description of scinitillation liquids 
emphasizing the scintillating fluid that was selected for this work, light capture 
with our chosen fiber, and photodection with our photodiode module.  Then 
methods to verify dose rate and spatial invariace with photons, the relation of 
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anterior beam SOBP depth and photocurrent collected, and estimation of our 
technique to register the prostate-rectal inferface using patient CT data, will be 
described.  The results of these experiments will then be presented, followed by 
a discussion of study limitations, scintillation dosimetry, alternate range 
verification techiques, and scintillation quenching.  We will conclude this chapter 
by evaluating our working hypothesis for specific aim 1. 
3.2 Materials and methods 
3.2.1 Light emission with scintillation 
 Scintillators are materials that exhibit luminescence when exposed to 
ionizing radiation (79).  The ideal scintillator should convert energy to light 
linearly and with high efficiency, should be transparent to its emission spectra, 
emit scintillation photons promptly, and have a refractive index close to glass for 
good optical coupling with a light guide or photocathode window (80).  There are 
three types of luminescence: prompt fluorescence, phosphorescence, and 
delayed fluorescence.  Of the three types, prompt fluorescence has the shortest 
decay time of 10-9 to 10-7 seconds.  The latter two types exhibit longer decay 
times of 10-3 to 102 seconds.  In the case of pulse mode photodetection, prompt 
fluorescence is the decay mode of use and delayed fluorescence and 
phosphorescence are considered extraneous noise.  In the case of current mode 
photodetection, long decay luminescence is proportional to incident ionizing 
radiation and therefore a useful fraction of the signal, however background noise 
must be removed between each measurement to remove residual luminescence 
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or wait a sufficiently long time to ensure the majority of trapped excitons 
decay(80). 
 While there are several forms of scintillators including inorganic crystals, 
plastic-based organic scintillators, and other potential detectors such as metal 
oxide semiconductor field effect transistors (MOSFET’s) and thermoluminescent 
dosimeters (TLD’s), liquid scintillator was selected for several reasons.  The 
detector needed to be inserted either inside or on the rectal balloon, which 
prohibited the use of large solid detectors.  The detector had to conform to the 
shape of the rectal balloon and the interface of the prostate and rectum.  The 
detector had to be sensitive in the SOBP region of the proton beam in real time 
as the patient is treated.   The real-time measurement requirement eliminated the 
use of TLD or film since these have to be removed to process the dose 
measurement (81).  The use of scintillating fibers (82-85) or MOSFET’s (86-88) 
for range determination was possible, however, these measured ionizing 
radiation over a small volume and are therefore only sensitive in the fall-off 
region of the proton beam.  All treatments required a treatment margin, so these 
detectors would only be useful for initial daily set-up.  The last reason to use 
liquid scintillation over other detectors was its relative insensitivity to radiation 
damage.  The detector remained in the beam for the entire treatment and was 
resistant to exposures as high as 105 Gy (80).  This radiation resistance enabled 
the re-use of the liquid resulting in substantially lower cost if the technique was 
used for daily fractionated radiation treatments. 
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 For these reasons, liquid scintillator was selected as our radiation detector 
for range determination during treatment.  The fluorescence process of the 
organic scintillators occurred in conjugated, aromatic molecules with rich π-
electron structures.  Fluorescence occurred when valence electrons are excited 
by ionizing radiation into their singlet energy states (Figure 13).  These molecules 
then lost energy in the form of vibration and internal conversion before decaying 
back to ground from the S1 state with the emission of a scintillation photon within 
nanoseconds.  Some excited valence electrons transitioned to triplet states 
through inter-system crossing and decayed to ground state by phosphorescence 
in milliseconds and at a longer wavelength.  From the T1 state, some electrons 
were re-excited to the S1 state and decay by delayed fluorescence.  Because all 
excited electrons decayed to S1 or T1 before luminescing, the overlap of 
absorption and emission spectra in scintillators was minimal resulting in very little 
self-absorption (80). 
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Figure 13: Diagram of the scintillation process (79) 
 The BC-531 liquid scintillation solution was selected (Saint Gobain 
Crystals, Newbury, OH) for this experiment.  The primary reason for the choice 
was the solvent that is used in this solution, linear alkyl benzene.  Most organic 
solvents used in commercially available scintillating solutions were highly toxic 
and carcinogenic such as benzene, toluene, xylene, cumene, and 
pseudocumene.  Linear alkyl benzene was a bound form of benzene that was 
considerably less toxic that other solvents.  It was also safe to use with most 
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solid commercial plastics.  Its National Fire Protection Agency (NFPA) health 
hazard classification was level 1 and its Hazardous Materials Identification 
System (HMIS) health hazard classification was level 1.  These classifications 
indicated a slight risk for temporary injury from exposure.  It was not listed as an 
acute or chronic health hazard by state and federal regulation.  Exposure may 
cause slight irritation of the eyes, skin, or lungs.  Ingestion may cause diarrhea, 
nausea, or gastrointestinal upset.  Considering the stated toxicity of the solution, 
our physicians were comfortable using this technique with appropriate 
prophylactic measures such as use of a secondary condom around the balloon 
and the use of gloves when handling the solution. 
Although safety and reactivity with plastics were the primary factors for 
determining the proper solution for our project, the other properties of the BC-531 
solution also matched the stated aims of our project.   The scintillator output 
efficiency was 59% of anthracene, which is comparable to other commercially 
available solutions from Saint Gobain Crystals.  Its emission spectrum was 
peaked in the visible blue region (Figure 14).    The refractive index of the 
solution was 1.47 which is very close to the refractive index of glass (1.5).  
Matching these indexes was important for proper optical coupling between the 
scintillator, light guide, and photodetector.  The solution’s electron density is 2.93 
X 1023, per cubic centimeter which was slightly lower but comparable to that of 
water.  This was ideal because the proton dose and range may be simulated with 
a water-filled balloon, and a large difference in electron density could have 
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modified the proton’s dose and range in the balloon from the predicted values at 
treatment simulation. 
 
Figure 14:  Emission spectra of liquid scintillating solution BC-531. 
3.2.2 Light capture with fiber optics 
 In order to convert collected light into an electronic signal, it was first 
captured.  To achieve light capture in our detector, a single fiber optic cable was 
fit through a commercial balloon stem (Radiadyne®, Houston, TX).  Water-filled 
rectal balloons were used in proton radiation therapy in our clinic as prostate 
immobilization devices. Initial studies of patients using water-filled balloons and 
receiving repeat CT imaging confirmed the reproducibility of the shape and 
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volume of the balloon on subsequent treatment fractions as well as the durability 
of the device in routine daily use (89).  35 patients were analyzed with a total of 
105 repeat CTs during treatment. The planning CT was registered to each repeat 
CT using an in-house developed 3D image registration method. The one 
standard deviations (1SD) and (mean; range) are 1.1 mm (1.1; -1.0 to 3.0 mm) in 
anterior-posterior (AP), 1.3 mm (-0.8; -3.4 to 2.0mm) in superior-inferior (SI), and 
0.5mm (-0.1; -0.1 to 1.0mm) in right-left (RL) directions respectively.  The balloon 
was expected to maintain its immobilization function when water was replaced by 
scintillation liquid.  
Light was emitted isotropically when ionizing radiation excited electrons 
within the scintillating solution.  The fiber was positioned such that it faced the 
anterior rectal balloon wall and the majority of the light emission.  A small fraction 
of the emitted light was incident on the face of the fiber, and this fraction was 
approximately the surface area of the fiber divided by the surface area of a 
sphere, 4πr2, where r was the distance from the emitted light to the fiber face.  A 
small portion of the incident light on the fiber face was reflected back into the 
solution.  The fraction of light polarized perpendicular to the plane of incidence, 
Rs, and inside the plane of incidence, Rp, were calculated with Snell’s Law 
(Equation 1) and Fresnel’s equations (Equation 2) as a function of the solution 
refractive index (n1), fiber core refractive index (n2), angle of incidence (θi), and 
angle of transmittance (θt) (90).   
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Equation 1: Snell’s law 
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Equation 2: Fresnel’s equations 
 
 Once incident photons were transmitted and refracted, they encountered 
the normal surface of the cladding with an angle greater than the critical angle 
(Equation 3) for total internal reflection (Figure 15).  This angle was set by the 
ratio of the indexes of the fiber core and cladding.  Those photons incident to the 
cladding at acute angles were partially transmitted through the cladding and the 
reflection portion quickly fell to zero after several reflections.  The net result of 
these two interfaces (solution/core and core/cladding) was that photons emitted 
within an acceptance cone were incident to the solution-core interface acutely for 
transmittance and the core-cladding interface obtusely for reflection to propagate 
the fiber length and reach the photodetector.  The half-angle of this acceptance 
cone is illustrated in figure 3 and expressed in equation 4 (90). 
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Equation 3: Critical angle for total internal reflectance 
 
Figure 15:  Internal reflection of a captured photon 
(www.edmundoptics.com) 
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Equation 4: Half-angle of acceptance in a fiber optic cable 
 Considering the previous conditions for light collection within our fiber, a 
step-indexed, multimode, optical grade fiber from Edmund Optics (Barrington, NJ) 
was selected.  This fiber had a large difference in the refractive index of the core 
(1.492) and cladding (1.402) for a large acceptance cone (half-angle: 30.5o in air).  
The calculated critical angle for internal reflection was 20o and the corresponding 
half-angle of acceptance in the solution was 20.3o for meridional rays, or rays 
that passed through the central axis of the fiber.  The half-angle of the fiber was 
slightly larger than this value if skew rays, or rays that are internally reflected but 
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do not cross the fiber axis, are considered.  The reflection coefficients calculated 
with equation 2 are displayed in figure 16 as a function of angle of incidence.  
Since the refractive index of the solution and core were similar, this value was 
close to zero and nearly all incident acutely angled photons were accepted. 
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Figure 16: Reflection coefficients of photons emitted inside the solution 
incident on the fiber face 
This particular fiber was the largest diameter fiber (2 mm) offered by this 
vendor with a protective plastic sheath.  Although larger fibers could potentially 
increase the fraction of light captured, they required a larger bend radius to avoid 
damage (Figure 17).  The minimum bending radius for these fibers was 25 times 
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their outer diameter, slightly greater than 5 cm.  For the fiber to face the anterior 
rectal wall, it must bend nearly 90 degrees in the distance from the balloon base 
to the middle of the stem.  The use of the 2mm fiber was the limit that we can use 
for controlled in vitro purposes.  For insertion into a patient, our detector would 
have to utilize a smaller fiber to ensure the fiber was not damaged during the 
insertion process.  Bending the fiber did have some positive benefit.  When the 
fiber was bent as shown in figure 17, the angle of incidence along the outer 
diameter was decreased, resulting in a rejection of modes with characteristic 
angles close to the critical angle of the fiber and a narrowing of the collection 
cone (90).  Normally this would be detrimental to light collection and users of the 
detector would have to ensure that the fiber remains straight during use.  
Bending the fiber acutely, as in our detection volume, automatically rejected the 
highest order modes.  This ensures that subsequent bends down the fiber did not 
affect the light output and that our light collection was consistent.  Even though 
fiber bending decreased total light collection, it ultimately increased the 
robustness of our detector. 
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Figure 17: Bend radius of a fiber optic cable 
Since the dose deposition of a flat anterior proton beam inside our solution 
and the corresponding light output was known along with the light collection of a 
fiber facing the anterior balloon surface, we could mathematically express the 
light collection within our fiber (Equation 5). 
 
Equation 5: Expression for two-dimensional light collection 
The total light emitted by our solution was proportional to the energy 
deposited [Joules] and scintillation efficiency [~ constant 3-5 %](79).  Thus, light 
emitted was the product of dose in units of the scintillation efficiency [~ 3-5 %], 
Grey [Joules/kg], the density of the solution [kg/cc], and volume [cc].  Not all 
emitted light was collected.  Only the light within the collection cone was 
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accepted into the fiber.  The volume of the cone subtended by the beam was the 
product of the distance of the fiber to the beam, k – x, and the tangent of the 
fiber’s half-angle of acceptance squared, multiplied the thickness of the cone, dx 
(Figure 18).  The portion of light incident on the fiber face from an isotropically 
emitting source was inversely proportional to the distance to the fiber face, ~ (k-x), 
squared.  A term was included in the denominator to scale (k-x) to the average 
radial distance on the cone at the point, (k-x).  This value was approximately 1.08.  
Therefore, light collected was independent of the distance from the fiber face to 
the anterior surface of the detector, k.  The remaining terms were product of 
constants, dose (x), and dx.  Thus for a large flat one-dimensional beam, light 
collected in our fiber was proportional to the integrated depth dose within the 
detector.  For a uniformly distributed dose, such as the proton SOBP, light 
collected was linear with depth of the beam within the detector. 
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Figure 18 Expression for light collection of a fiber facing the anterior 
detector surface 
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3.2.3 Light conversion to current with photodetection 
 Though, there were several options to choose from, to detect scintillation 
light, a photodiode was selected for several reasons.  Photodiodes were cheaper 
than alternatives such as photomultiplier tubes (PMT) or charge-couple device 
(CCD) cameras.  They were also insensitive to magnetic fields. This was 
extremely important if the detector was inside the treatment room during 
measurement.  They typically had a greater fractional yield of photoelectrons per 
incident photon, or quantum efficiency, than PMT’s.  They were mechanically 
rugged and required only battery power for operation (80).  These features were 
very important if the device was used daily during a patient’s fractionated 
treatment.  PMT’s required a stable high voltage source because the detector’s 
gain was highly dependent upon the applied voltage to the dynode structures 
during electron multiplication (Hamamatsu PMT handbook).  The supporting 
electronics for PMT operation were bulky and non-ideal for clinical use.  CCD 
cameras required external cooling to achieve a sufficient signal-to-noise ratio for 
precise scintillation detection.  The cooling process can take more than 30 
minutes, which may be impractical for repeated use. 
Photodiodes ideally generated current proportional to the light incident on 
their photocathode.  As scintillation light reached the photocathode of the 
photodiode, valence electrons originating from the doped impurities in the crystal 
lattice were excited from the valance band into the conduction band (80).  The 
energy difference between these bands was called the band gap energy and was 
1-2 eV for silicon photodiodes.  The typical energy of an incident scintillation 
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photon was typically 3-4 eV, sufficient to generate electron-hole pairs in the 
cathode.  The bias voltage then forced current across the depletion region to the 
diode’s anode.  This current could then be measured with a digital volt meter or 
oscilloscope across a load resistor or directly with a current measurement tool 
such as an electrometer. 
We chose the DET36A biased detector (Thorlabs, Newton, New Jersey) 
for our measurements.  This detector was a silicon PIN photodiode that had a 3.6 
mm by 3.6 mm active area sensitive to photons from 350 to 1100 nm (Figure 19).  
The specified dark current was 0.35 nA with a 10V bias voltage.  The internal 
electronics was enclosed in rugged aluminum housing and included a BNC 
output, a battery check switch, and a threaded optical coupler for adapting 
lenses, filters, or SMA/FC fiber adapters.  The output of the detector was linear 
with incident light intensity up to 1 mA output.  The lifetime of the included 12 V 
bias battery was stated 40 hours at 1 mA output current. 
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Figure 19: Spectral response of the DET36A module (www.thorlabs.com). 
An SMA adapter was threaded into our detector.  The SMA connector was 
then drilled to 2 mm in diameter to match the diameter of the selected optical 
fiber (Figure 20 top).  The fiber was then glued into the connector and its face 
was polished incrementally with 800 to 2000 grade abrasive paper to provide 
quality optical coupling to the surface of the photodiode.  After threading the fiber 
to the surface of the diode, black electric tape was applied over the connector 
and thread to maintain the coupling.  An additional layer of aluminum foil and 
electric tape was applied to shield the residual light leakage. 
 The photocurrent generated by our detector was measured with a Keithley 
602 electrometer (Keithley Instruments, Inc, Cleveland, Ohio).  To connect the 
detector to the electrometer, a male/male BNC adapter and female BNC to a 2 
lug triaxial male adapter was used to mate the female BNC output of the detector 
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to the female triaxial input of the electrometer (Figure 20 middle).  The 
electrometer was set to current mode in nanoamperes (10-9 A) for all 
measurements.   
 To generate a digital signal for data analysis, the analog output on the rear 
side of the electrometer was connected to an analog-to-digital converter (ADC).  
The analog output of the electrometer provided voltage representing the selected 
scale of the front of the instrument, The DATAQ DI-158 programmable ADC was 
selected for USB interface with our computer.  This four-channel ADC had 12-bit 
resolution over +/- 64 Volts, an internal gain range from 20 to 29, and a maximum 
sampling frequency of 14.4 kHz.  Based on preliminary photon measurements 
with our detector system, photocurrent from 0 to nearly 1 nA was observed at 
maximum dose rate with an open field.  Therefore the internal gain was set to 64 
to best match the estimated current range and to optimize the 12-bit resolution 
(+/- 2048 steps) of the ADC for approximately 0.488 picoampere measurement 
precision. 
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Figure 20: Photodiode module (top), electrometer (middle), and analog-to-
digital converter (bottom) for converting emitted light into a digital signal  
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 Operation of some of the programmable features on the ADC required the 
use of Dataq’s WinDAQ software (DATAQ Instruments, Inc., Akron, OH).  Use of 
the free version of the software throttled our sampling frequency to 240 Hz; 
however the software had an option to average the sampled data (at 14.4 kHz) to 
the 240 display frequency.  This significantly reduced variation of the background 
noise, and increased the signal-to-noise ratio for the detector.  The vendor 
software also provided recording features and data processing options.  However, 
we interfaced both devices with LABVIEW (National Instruments, Austin, TX) for 
future integration of the detector with the dual wedge range shifter. 
 With the WinDAQ software operating in the background, the LABVIEW 
drivers provided by the vendor passed the scaled data to our LABVIEW virtual 
instrument (Figure 21).  The LABVIEW virtual instrument had an on/off switch, 
channel selector, numerical data register and graphical data real-time display.  
The virtual instrument used the ActiveX controls of the driver to initialize the ADC, 
select the measurement channels, and obtain the scaled data from WINDAQ.  
The program used a timed loop and shift register to retrieve the data, display the 
data on the front panel, and generate an array with the measurements.  The 
program then exported the array in a tab-delimited spreadsheet for subsequent 
analysis. 
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Figure 21: Labview virtual instrument for our detector. 
3.2.4 Experiment methodolgy 
 Before beginning the experiments, 60 mL of liguid scintillation solution was 
inserted into commercially available endorectal balloons to test the compatibility 
of the balloon material with the chosen scintillation solution.  The first balloon 
selected, a latex balloon from MEDRAD (MEDRAD, Inc., Pittsburgh, PA), was 
damaged after the solution was left several days in the balloon.  When the 
balloon was removed from the experimental phantom, the stem ripped from the 
balloon at the base.  The same test was then attempted with the Radiadyne 
(RadiaDyne, LLC, Houston TX) balloon made of a plastic material.  After two 
weeks of holding the solution, the balloon maintained its shape and structural 
integrity. 
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The preliminary measurements were made in a light shielded IMRT film 
phantom (Figure 22).  A 2 mm fiber was inserted into the vial straight down from 
the top of the volume, collecting light from most of the detector volume.  External 
fiducials were used to mark align the center of the detector volume and the 
treatment isocenter for the first measurements.  After the fiducials were affixed to 
the phantom and the vial was in its permanent position, the phantom was imaged 
with a CT scanner.  Using the CT data, the dose delivered to the vial during the 
measurements was calculated and compared with the generated photocurrent.   
 
Figure 22: IMRT film phantom for preliminary measurements 
For the first set of measurements, the 10 X 10 cm2 open field generated 
photocurrent was measured with dose rates of 100, 200, 400, and 600 monitor 
units per minute for 50, 100, 200, and 300 monitor units respectively.   The real-
time current generated by these measurements was background subtracted and 
correlated with the dose rate delivered to the solution with the Pearson 
parametric correlation. 
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Once dose linearity was established, the next set of photon 
measurements investigated the sensitivity of light collection as a function of 
position within our detector.  The MLC shaper software (Varian Medical, Palo 
Alto, CA) was used to vary the position of the beam in real time.  This software 
conveniently modified the multi-leaf collimator control points within the Pinnacle 
treatment planning system (Royal Philips Electronics, Amsterdam, The 
Netherlands).  Using the preliminary detector prototype and IMRT film phantom, 
we measured the photocurrent with a 3 mm wide MLC window that traveled at a 
constant rate across the field width from the anterior to posterior portions of the 
phantom (Figure 23).  Figure 23, illustrated the 3mm sliding window segment 
delivered to the test phantom in the Pinnacle treatment planning system with 
isodose lines ranging from 60% (red) to 10% (white) of the max point dose within 
the phantom.  The length as well as the width of the sliding window was varied to 
investigate these factor’s effects on the measured current.  To investigate the 
relation of light collection as a function of distance from the fiber face, the 
collimator was rotated 90 degrees and a 4 cm by 3 mm sliding MLC window was 
delivered superiorly from the bottom of the vial (top of figure) past the face of the 
fiber.  These measurements suggested that redesign of the detector with the 
fiber facing the anterior detector surface may result in superior performance. 
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Figure 23: MLC sliding window in the test phantom 
After the previous measurements, a second detector was fabricated with 
the fiber facing the anterior detector wall.  The Radiadyne outer balloon was 
removed and a hole was drilled through the stem at 45 degrees.  A light-tinted 
glass vial of comparable volume and length to the commercial balloon was used 
as a surrogate in all of the measurements.  The plastic cap of this vial was drilled 
with holes to the exact dimensions of the balloon stem and fiber to ensure that 
the vial would remain liquid tight during our experiments.  After threading the 
balloon stem and fiber through the plastic cap, the fiber was inserted into the 45 
degree hole drilled into the stem of the balloon and fixed into position with Krazy 
glue.  The holes at the base of the vial cap were also coated with Krazy glue to 
close the residual gap between the fiber, stem, and cap.  The vial was then filled 
with 60 mL of liquid scintillator.  The vial remained closed for the duration of all 
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experiments.  The position of the stem and fiber within the balloon was 
subsequently verified by CT (Figure 25). 
A custom-made deformable phantom simulating a male pelvis, was used 
to measure radiation doses in the (simulated) prostate target and anterior rectal 
wall. The phantom, as shown in Figure 24, was made of tissue substitute 
materials by blending epoxy resins, urethanes, water based polymers and other 
proprietary materials (CIRS, Inc., Norfolk, VA). The phantom had an opening for 
inserting the rectal balloon and scintillation detectors designed in this study. 
When the balloon was inflated, the rectum displaced the prostate target 
anteriorely, which simulated the conditions of rectal filling in a patient treatment.  
The deformable phantom was used to simulate a patient treatment and test our 
scintillation detectors system before applying this technique to real patients.   
 
Figure 24:  A custom-built deformable pelvic phantom 
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Figure 25: Light vial with machined stem and fiber inserted into our 
anthropomorphic phantom 
After construction of the light detection portion of the beam positioning 
device, the precision of the detector was measured.  To measure the precision, a 
measurement was performed with a single proton beam incident upon a water 
phantom that holds the scintillation detector (Figure 26).  The phantom was 
irradiated at the University of Texas M D Anderson Proton Therapy Center in 
Houston, TX on the G1 rotatable beam gantry. The beam delivered 200 MU to a 
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depth of 17.7 cm with a 10 cm square field size and 10 cm SOBP at 
approximately 270 cm SAD in physics mode.  Physical depth to the anterior 
detector interface was 11.7 cm.  A variable thickness of known attenuator 
(polystyrene slabs) was repeatedly moved into the distal fall-off of the beam in 
order to determine the detection threshold as a function of beam depth.  The 
initial build-up thickness was 6 cm.  The current was then measured with build-up 
of 5.5 cm to 6.5 cm in 1 mm increments.  We then measured with build-up 
thickness of 5 cm, 4.5 cm, and 4 cm.  Pulses were background subtracted and 
integrated over the 200 MU delivered to generate the photocurrent as a function 
of SOBP depth into the detector.  Since the radiological depth to the detector 
surface was unknown, the known relation for light collection was exploited to 
determine the point where the SOBP reaches the detector.  Since the relation is 
linear and builds in the fall-off region, a bilinear fit of the SOBP and fall-off 
portions of the relations was used to find the point where the relation diverges.  
The origin was then reset to this point.   
The reproducibility of the light output as a function of beam position 
determined the uncertainty of the light collection device.  Since treatment in 
physics mode resulted in uneven proton spills, each spill was normalized to the 
number of monitor units delivered.  The standard deviation of these normalized 
pulses was then measured for each SOBP position and the coefficient of 
variation at each point was calculated.  For illustration purposes the error bars on 
the SOBP depth versus photocurrent reflected the coefficient of variation of the 
proton spills for each point.  Using these error bars and the measured gradient of 
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the relation when the SOBP is inside the detector, the spatial resolution of our 
technique was determined assuming a single proton spill was used to determine 
depth. 
 
Figure 26: Experimental apparatus for measuring the photocurrent as a 
function of SOBP depth 
Although phantom measurements provided an estimation of the device’s 
precision as a function of SOBP depth within the detector, it did not take into 
account the variation of dose and subsequent light emitted as the balloon and 
target organs deform in shape.  For this experiment, the worst case scenario was 
assumed, that the scintillated light emitted and captured is proportional to the 
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mean dose in the detector volume.  Estimation of in vivo uncertainty of the light 
output of our scintillator is the worst case scenario because light collection was 
specific to the depth of the proton beam within the detector.  The prototype was 
theoretically insensitive to some deformation as discussed in figure 18.   . 
Eight prostate cancer patients enrolled in an IRB-approved protocol 
contributed 8 reference and 19 total daily CT image sets for this study.  Each CT 
data set was imported into the Pinnacle treatment planning software for 
dosimetric calculations.  A single beam from the lateral direction was created for 
delivery of the sliding MLC window.  To create the aperture for the window, a 
2mm diameter circular ROI was created inside the anterior edge of the rectum on 
each axial slice.  This ROI was then expanded anteriorely by 3 mm.  The final 
ROI was generated by subtracting the anterior point ROI from the expanded, 
leaving a 3mm wide ROI tightly abutting the anterior rectal wall.  The MLC 
segment was then created by blocking the beam to this ROI (Figure 27).  To 
simulate the sliding of this segment in Pinnacle, 10 additional beams were 
generated from the original beam with an isocenter displaced anteriorly and 
posteriorly in 1mm increments from -5mm to 5 mm. 
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Figure 27: Beam-eye-view of the MLC sliding window segments 
Each segment was set to deliver 500 MU in order to generate the required 
dose display precision in Pinnacle.  The dose grid was set at 3 millimeter 
resolution.  The mean rectal dose delivered to the entire rectum was then 
calculated in Pinnacle. The mean rectal dose of each segment was then plotted 
against the beam position to generate the reference dose-position relationship 
(Figure 28) on the patient’s reference CT.   
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Figure 28: Mean rectal dose as a function of segment distance from the 
ARW 
This relation was then compared to similar relations calculated on the 
patient’s daily CT image sets for simulated device registration based on mean 
rectal dose and thus light emitted within the balloon.   These daily graphs were 
then manual shifted to match the reference relationship and obtain the daily 
corrective shift to align the treatment at the anterior rectal wall (Figure 29).  In the 
cases were the slopes were significantly different, the relations were matched at 
the origin on the reference CT when possible. 
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Figure 29: Manual registration of dose-position relation for alignment 
The same CT image sets were then imported in our in-house CT 
registration software, Computer-aided Targeting (CAT) (59, 91).  A one-
dimensional alignment of the anterior rectal wall was manually determined to 
validate the dosimetry method, as shown in Figure 30.  In cases where the rectal 
position rotated, alignment was attempted at the anterior rectal wall near the 
center slice of the prostate. 
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Figure 30: CT registration of ARW in CAT 
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3.3 Results 
3.3.1 Preliminary photon measurements 
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Figure 31: Photocurrent as a function of open-field dose rate 
 The results of the open-field dose rate dependence were illustrated in 
figure 31.  The ADC for these measurements was set to 60 Hz and internal gain 
set to one. This was the reason the data appears to have low resolution (both 
axis).  There were also issues with the LABVIEW drivers incorrectly fetching the 
scaled data, so the effective sampling rate was slightly less than 60 Hz.  These 
issues were resolved in later experiments by changing the baud rate of the ADC, 
and fully leveraging the dynamic range of the ADC by setting the gain.  The 
periodic signal variances shown in the figures were specific to one linac used in 
measurement.  The magnitude of the variance illustrated in figure appeared to be 
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dependent on the dose rate; however it did not appear to be linearly correlated.  
The background was very stable, approximately 183 picoamperes.  Variation of 
the 100 and 200 MU/min rate appeared to be similar, as do the 400 and 600 
MU/min rates.  These measurements were then background subtracted and 
averaged to investigate the linearity of signal output as a function of dose rate. 
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Figure 32: Correlation of mean photocurrent with the open field dose rate 
 Figure 32 illustrated the average background subtracted photocurrent as a 
function of dose rate.  The photocurrent generated was slightly greater than 1 
picoampere per MU/min.  The photocurrent was highly correlated with dose rate 
(p <0.001).  The standard deviation, as shown by the error bars in the figure 32 
and displayed in Table 1, appeared to be similar in magnitude for the 100 and 
200 MU/min dose rates and the 400 and 600 MU/min dose rates. 
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Dose 
Rate 
[MU/min] 
Average 
signal [pA] 
Standard 
Deviation 
100 102.70 11.78
200 209.86 13.17
400 410.32 23.54
600 616.86 20.96
Table 1: Photocurrent as a function of open-field dose rate 
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Figure 33: Photocurrent generated by reduced size sliding windows 
Figure 33 showed the current generated by a 4cm by 10cm MLC window 
as it traveled across the beam aperature. The resulting dose was delivered 
anteriorely through the IMRT film phantom and the detector volume.  The 
measured current peaks as the window reached the fiber axis.  We compared the 
4 cm X 10 cm X 3 mm window with a 4 cm X 10 cm X 5 mm window and 2 cm X 
10 cm X 5 mm window.  As we anticipated, increasing the width of the gap 
increased our signal and reduction of the window length decreased the dose and 
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signal.  Reduction of the window length was clearly the dominant of the two 
factors.  If this technique was implemented for IMRT patient set-up, window size 
reduction could potentially decrease extraneous patient dose. 
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Figure 34: Photocurrent generated from 4X10 cm MLC window with 1 cm 
travel length 
Figure 34 illustrated a 4 cm X 10 cm X 3 mm window with a one 
centimeter travel length starting five millimeters inside the detector and traveling 
to the outside of the detector wall.  This particular technique could be used 
localize patients with minimal dose before the treatment.  The short buildup 
region in the first 3 seconds showed the MLCs opening to their 3 mm width.  The 
dose steadily decreased as the window moves away from the position of peak 
sensitivity in the center of the volume.  This figure was used again to correlate 
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the photocurrent generated as a function of sliding window delivered dose as 
estimated in the Pinnacle treatment planning system documented later in this 
chapter. 
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Figure 35: Photocurrent generated from a MLC window traveling up the 
detector volume 
 Figure 35 illustrated the photocurrent generated as the window travels 
towards the fiber face from the bottom of the detection volume.  The width of the 
photon beam penumbra was fairly large, approximately 2 cm, which led to an 
initial buildup of current signal.  Once the dose delivered by the window was 
completely inside the vial, the output current signal was constant for both dose 
rates until the window reaches and passes the face of the fiber.  This 
measurement validated Equation 5.  The increased capture fraction of photons 
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emitted from any point within the volume by the fiber face was canceled by the 
decreased cone volume as the window reached the detector.   
3.3.2 Anterior Proton Beam Simulation 
 Figure 36 illustrated the detection of a single proton spill when the anterior 
detector interface is mid-way through the proton SOBP (5 cm).  The measured 
spill was consistent with the known properties of of the Proton Therapy Center 
synchrotron.  A proton spill from the synchrotron was approximately 0.5 seconds 
in duration.  Each spill was approximately 2 seconds apart.  During each spill, the 
range modulator generated a uniform dose delivery to the entire SOPB.  To 
obtain a uniform dose, the majority of the peaks were weighted near the distal 
end of the SOBP.  The modulator wheel rotated at approximately 6.6 Hz.  For 
each rotation, the wheel completed three modulation cycles, in and out of the 
detector at the distal end of the SOBP.  Based on these properties, we expected 
our signal to build as the beam moved into the detector and decrease when the 
beam was retracted.  Therefore, our signal had a frequency of 20 Hz within the 
spill.  We observed exactly 10 peaks in the signal with each spill as shown in 
figure 36.   
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Figure 36:  Proton spill with the detector anterior surface in the middle of 
the proton SOBP 
Figure 37 illustrated a series of spills at a position mid-SOBP compared to 
a series of spills near the therapeutic range.  Even with the SOBP well within the 
detector, the peak signal was not consistent.  The cause of these discrepancies 
was the delivery of the beam in physics mode.  When using physics mode, the 
tolerances of the gantry were relaxed to lower the cost of running the beam.  This 
led to a slight variation in the initial beam energy or loose windowing of the 
modulator wheel.  Either one of these potential effects could cause a variation in 
the observed range (signal peak) mid-spill.  The figure also illustrated that this 
variation is much more apparent at the distal end of the SOBP (therapeutic 
range).  Theoretically, some range modulation peaks should reach the detector 
and others should fall short.   
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Figure 37: Comparison of proton spills mid-SOBP with spills at therapeutic 
range 
 Figure 38 showed the relationship of integrated photocurrent over the 200 
MU delivery as a function of SOBP depth within the detector.  The relation 
showed gradual signal buildup in the distal falloff region and linear output in the 
SOBP region as predicted in Figure 18. Since the relationship diverged from 
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linearity at therapeutic depth, the measurement origin was reset with a bilinear 
fitting of the signal with the distal falloff and dose within the SOBP.  This fit was 
rounded to the nearest millimeter.  The fit predicted the SOBP reached the 
detector approximately 2 mm further than the measured 11.7 cm inside the 
phantom to the anterior detector wall.  This adjustment was reasonable because 
the tissue-equivalent material had a slightly higher stopping power than water.  
The standard deviation of the spills was 19.5% at our original origin (-2 mm 
position) and decreased to approximately 11% in the saturation region.  The 
linear fit of the measured data in the SOBP region yielded a gradient of 1.0183 
nC/cm.  Pulse variation was 17% or 0.052 nC at 2 mm depth corresponding 
approximately 0.51 mm considering the signal gradient in the SOBP.  If in vitro 
detector uncertainty was the only source of uncertainty, our margin to treat with 
95% confidence would be approximately 1 millimeter. 
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Figure 38: Photocurrent generated as a function of SOBP depth 
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3.3.3 In Vivo treatment Uncertainty 
 Figure 39 illustrated the agreement between the one-dimensional 
registration based on the rectal dose/ light emitted and the one-dimensional 
manual registration of the anterior rectal wall using the CAT, CT-to-CT 
registration software. The two values were highly correlated and the standard 
deviation of the difference between the two alignment techniques was 1.1 
millimeters, and the average magnitude of differences was 0.76 millimeters. 
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Figure 39: The corrective shifts generated from the sliding MLC technique 
compared with manual registration 
 To validate the use of mean dose as a surrogate for light output and 
photocurrent signal, we compared the current signal in picoamperes with the 
simulated delivery of the 4 cm sliding window as calculated in the Pinnacle 
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treatment planning system (Figure 40).  The original measurement was obtained 
from Figure 34.  The series in blue was the measured current signal with delivery 
of the 4 cm by 10 cm by 3 mm sliding window.  We sampled Figure 34 into 10 
equidistant measurements for comparison with the treatment planning dose. 
Mean dose calculated from the treatment planning system was highly correlated 
with the measured photocurrent (p<0.01) 
 
Figure 40: The measured current signal [pA] and mean dose [cGy] as a 
function of window position. 
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3.4 Discussion 
3.4.1 Summary and discussion of results and aim 
 In summary, we built a device for detecting the fall-off of an anterior proton 
beam to reduce range uncertainty during treatment.  This device consisted of a 
liquid scintillation filled rectal balloon with a single fiber machined through the 
stem at an angle slightly greater than 45 degrees.  When the fall-off reached the 
anterior balloon surface, scintillation light was emitted isotropically in proportion 
to the dose and corresponding energy deposited within the fiber’s collection cone.  
This light was collected by the fiber and guided to a silicon photodiode.  The 
diode generated current in proportion to the incident light.  This current was 
measured by an electrometer and converted to a digital signal for computer 
analysis. 
 Our aim for this chapter was to design an in vivo proton beam detection 
device located within a rectal balloon that could detect the distal fall-off of a 
proton beam within 2 mm (95% confidence interval).  To evaluate our design, we 
measured the photocurrent produced by an anterior proton beam in our 
anthropomorphic phantom and detector prototype as a function of SOBP depth 
from the anterior interface of the detector.  By investigating the signal gradient 
and variation of the individual proton spills, we approximated the uncertainty of 
positioning the patient with each proton spill in real-time.  The 95 % confidence 
interval at 2 millimeters from our corrected interface was approximately 1 mm.  
We wanted to extrapolate this technique and corresponding uncertainty for use in 
a patient.  Since the total light output was a function of the energy deposited in 
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the scintillator and the rectal volume was nearly constant in patients with 
endorectal immobilization, we used mean dose as a surrogate for light output in 
the treatment planning system.  The relation of beam position with rectal dose 
was a function of the distance of the beam from the prostate-rectal interface and 
the shape of the balloon.  Therefore we simulated set-up with the device by 
registering patient’s prostate-rectal interface with an MLC sliding window induced 
rectal dose.  We then compared alignment with the mean dose gradient to 
manual one-dimensional alignment with CT registration software to isolate output 
variation induced from shape deformation of the balloon.  The standard deviation 
of agreement was 1.1 millimeters.  Assuming that the in vitro and in vivo 
uncertainty sources were independent and random, the composite 95 % 
confidence interval was approximately 2.4 millimeters in each direction.  Thus, 
we narrowly missed our aim of 2 millimeter precision.  However, considering the 
study limitations and the potential for improvement as discussed in the 
proceeding sections, our initial 2 millimeter guess was an excellent. If we relax 
our 95% confidence criteria to 90%, the interval is exactly 2.0 millimeters. 
3.4.2 Design limitations 
 There were several limitations in design, implementation, and testing of 
our device precision.  The first limitation of our device was the use of liquid 
scintillation as our radiation detector.  The solution was slightly toxic and 
therefore required special handling, storage, and prophylactic safety measures 
for use in patients.  The solution was also noxious and difficult to clean when spilt.    
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Additionally, exposure of the liquid to air resulted in signal quenching, so airtight 
storage was necessary to ensure signal integrity. 
 The second limitation of the detector was the energy-dependent 
quenching of the solution in the distal fall-off.  Only a small fraction of the energy 
deposited within the solution was converted into light.  For the ideal scintillator, 
the fluorescence yield was proportional to the energy loss as in equation 6. 
dx
dES
dX
dL =  
Equation 6: Ideal scintillator output 
 In equation 5, the light output of the scintillator per unit pathlength was 
proportional to the linear stopping power multiplied by the efficiency of the 
scintillator.  This relation held for electron energies in excess of 125 keV, but this 
threshold was significantly higher for larger charged particles such as protons 
(80).  To account for LET-dependent quenching from damage molecules in the 
solution, an additional term was added to the denominator in Birk’s formula (92) 
(Equation 7). 
dx
dEkB
dx
dES
dx
dL
+
=
1
 
Equation 7: Birk’s formula for quenched scintillator output 
 For low LET radiation, this formula reduces to equation 6 and the light 
output is directly proportional to the energy deposited in the solution.  For high 
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LET radiation, scintillation efficiency approached the empirically determined 
value, S/kB, where B was the probability of damaging a fluor in the solution and k 
was the probability that the damaged molecules will quench the excitons in the 
solution.    These terms were unable to completely account for quenching, which 
continued to increase with increasing LET of low energy charged particles..  This 
additional quenching may have been due to interaction between mutually excited 
electrons as the ionization density was increased(93).  To account for quenching 
that continued to scale with decreasing energy, an additional quadratic term was 
added to the denominator in Equation 8. 
2
1 ⎟⎠
⎞⎜⎝
⎛++
=
dx
dEC
dx
dEkB
dx
dES
dx
dL
 
Equation 8: Birk-Chou model for LET-dependent quenching 
 The three terms, S, kB, and C were experimentally fit and provide good 
agreement with measured values While several authors have recently discussed 
liquid scintillation for external beam dosimetry (94, 95), few have modeled proton 
quenching in scintillators ((96), Beddar and Siebers 1995) and one author 
experimentally determined quenching in BC-531 (97).  Beddar et al. used a 
plastic tank and CCD camera system for quality assurance dosimetry of a proton 
pencil beam.  Scintillation measured depth dose deviated from the 
measurements made with a parallel plate ionization chamber from three factors, 
the focal depth of the lens system, optical blurring, and scintillation quenching.  
The absolute efficiency of the scintillator at the Bragg peak of a 120 MeV beam 
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was approximately 70%.  More troubling for relative dosimetry purposes, was the 
observed degradation (widening) of the falloff, however, this was primarily due to 
optical blurring and would not be present if the light was collected closer to the 
source.   
 We anticipated a very small deviation (sub-millimeter under-estimation) in 
the position of the distal fall-off when the quenched depth dose was integrated 
with our detector.  This value would be approximately the distance to agreement 
(relative) between the quenched depth dose and measured depth dose.  
Fortunately, the strongest factor in quenching was the initial proton energy and 
depth.  Therefore, most of the deviation would be systematic and could be 
mathematically modeled with Monte Carlo (96).  Then the predicted range with 
our technique could be corrected based on the initial energy of the proton beam 
and the measured depth. 
 Another potential limitation of our design was due to the dependence of 
light collection efficiency on the coupling efficiency at each optical interface (98).  
Although we do not couple to our scintillator as in scintillating fiber dosimetry, we 
can still lose a large amount of light at the coupling of our fiber to the face of the 
photodiode.  Loss of some of the light at the coupling was not detrimental to our 
goals, since we observed signal well above background while still in the fall-off 
portion of the beam.  However, we maintained the same coupling at the 
photodetector for all of our measurements.  The only way to maintain identical 
coupling for in vivo application of our device was to use the same exact system 
for all measurements.  Reuse of the balloon between patients may not be 
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feasible.  Therefore, we would re-couple at the diode if the balloon and complete 
fiber length were fabricated together or we could apply a fiber adapter at the 
base of the balloon and reuse the length of fiber leaving the treatment room.  The 
variation in the re-coupling with a fiber adapter would be similar to the 
measurements of Ayotte et al. (98) who investigated variance in coupling to 
scintillating fibers.  They reported 10% variance with proper fiber preparation and 
consistent procedures.  This variance would significantly contribute to the spatial 
resolution of our detector and potentially increase the distal margin needed to 
ensure treatment confidence. 
3.4.3 Study limitations 
 The first study limitation was the operation of the synchrotron gantry in 
physics mode.  When in physics mode, the tolerances for proton energy and 
range modulator windowing were looser.  Therefore much of the observed 
variation in the proton spills may not reflect treatment in clinical mode in an actual 
patient.  To better estimate the precision of our technique, we should repeat the 
experiment by generating a treatment plan in Eclipse and delivering the plan in 
clinical mode.  We could repeatedly deliver the plan with different amounts of 
degrading material in the beam to generate the sensitivity of our detector as a 
function of SOBP depth.  Since the measured precision with this technique 
should be considerably less, we could still establish feasibility with our previous 
measurements. 
 The second study limitation was the use of photon mean dose in Pinnacle 
to estimate the in vivo uncertainty of our device.  Mean dose was an excellent 
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surrogate for total light emitted inside our balloon and light collected with our 
initial prototype design.  Our latest prototype was only sensitive to the depth dose 
between the fiber and anterior rectal wall.  The light collection of our prototype 
along with the sharper dose fall-off of the proton beam in the balloon should lead 
to a much smaller in vivo detection precision.  Since the precision measured was 
close to our stated aims, we deferred these measurements to a later date. 
 The final limitation of our study was the ability of the registered plan to 
cover the clinical target volume.  Assuming we registered the plan to a point on 
the anterior rectal wall, deformation of the target organs, particularly rotation (44), 
may move the target slightly out of the treatment field.  Use of two fibers, one at 
the base of the prostate and one at the apex, could theoretically detect rotation 
during treatment.  The precision of each fiber should be identical to our 
measurements.  Proper range correction to account for a rotation in the target 
organs could be challenging. 
3.4.4 Alternative range verification techniques 
 Lu et al (99, 100) has investigated the use of point dosimetry (MOSFET-
based) at the anterior rectal wall at MGH for in vivo range verification.  This 
method exploited the range modulation in the proton SOBP and approximated 
the residual range of the proton beam based upon when the Bragg peak reaches 
the point detector within the patient.  Each point within the Bragg peak had a 
unique periodic dose rate was used as a “ruler” for in vivo range verification.  The 
precision of this technique was dependent upon many factors such as variation 
of the spectral fluence at depth caused by heterogeneities in the patient. It was 
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also highly dependent upon the temporal resolution of the detector, since their 
technique was dependent on reproducing the dose rate at a point with fidelity.  
At this point in time, the MGH group does not have the capability to 
synchronize their measurements with the range modulator wheel and gantry in 
vivo. They have proposed a second method for range verification using only the 
dose measured at a point at the anterior rectal wall.  Liquid scinitllator was 
selected for this thesis due to its sensitivity in the SOBP region of the beam.  The 
method that Lu et al proposed artificially created a gradient in the SOBP by 
treating with two beams, one with increasing dose in the SOBP and the second 
with decreasing dose in the SOBP.  The sum of these two beams generated a 
uniform dose in the SOBP.  They then have an algorithm that reconstructed the 
range based on the ratio of the doses delivered to the point by both beams with 
approximately millimeter precision.  This method could provide reliable 
interfractional correction, however real-time correction would be slightly more 
challenging. 
Another potential range verification method was PET verification (101-
104).  When the patient’s tissues are irradiated with protons, positrons were 
emitted from activated isotopes e.g., 11C, 10C, 15O within the patient.  The activity 
can then be predicted based on the range of the protons, total dose, dose rate, 
and dose distribution within the patient.  The positron decay can be measured 
either in-room or shortly after therapy by moving the patient into a nearby 
imaging suite.  The primary limitations of this method for range verification were 
the relatively short life-time of the isotope, biological wash-out, and the inherently 
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low resolution of the imaging modality.  If the method were used for real-time 
tracking, i.e. 4DPET, the disadvantages of the modality would be compounded 
with the relatively low counting statistics from obtaining images over a very short 
duration.  While PET verification had the potential to improve proton therapy for 
all disease sites, its performance for verification at the anterior rectal wall will not 
out-perform direct measurement techniques. 
3.5 Specific Aim 1 conclusions 
 A scintillation filled endorectal balloon was designed for real-time 
determination of an anterior proton beam’s range.  The goal was 2 millimeter 
precision and that goal was nearly met with an estimated 95% confidence 
interval of 2.4 millimeters.  Given the precision of the initial measurements, use of 
this technique for real-time adaptive proton therapy with our technique was 
certainly feasible.  The estimated in vitro precision of our technique also 
exceeded the measured precision of other range verification techniques and was 
simpler to clinically implement.  Further development of this technique was 
needed to translate this technology into the clinic.  
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Chapter 4: Development of a dual wedge range shifter 
4.1 Introduction 
Specific Aim 2: Develop a computerized external proton beam range shifter 
to modulate proton beam energy/range. 
Working hypothesis: An external proton beam range shifter can modulate proton 
beam energy/range and localize the distal fall-off of a single anterior proton beam 
to the anterior rectal wall within 2 mm (95% confidence interval). 
To adapt the incoming beam energy to the daily variation of the rectal wall 
position, a range shifter was placed in the beam path between the end of the 
proton beam nozzle and the anterior skin surface of the patient, as diagramed in 
Fig. 12. The range shifter was a pair of triangularly shaped Lucite attenuators, 
one which was fixed and another which was dynamically adjusted. The thickness 
of the range shifter was controlled precisely by a stepping motor, which 
controlled the horizontal positions of two triangular objects. A thicker range shifter 
in the beam path will pulled the distal proton beam edge anteriorely from the 
prostate and rectum interface, sparing the rectum from excessive (overshooting) 
radiation. A thinner range shifter, on the other hand, increased the proton range 
to ensure that the posterior coverage of the prostate target to the adequate 
prescribed dose level.  The goal for this chapter was to develop this wedge 
shifter based on observation of anatomic deformation of prostate cancer patients 
and determine the precision of the range system to degrade the proton’s range 
from a calculated value. 
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4.2 Methods and materials 
4.2.1 Degradation of the beams energy and range 
 Most proton synchrotrons or cyclotrons employed some method of 
reducing the proton’s energy and range by placing attenuating material in the 
beam’s path.  Inside this material, proton’s lost energy from multiple Columbic 
interactions with electrons resulting in a reduction of the proton’s energy and 
residual range (105).  Some of the protons interacted with the nuclei in the 
attenuating material and deposited most of their energy, resulting in a loss of 
proton fluence and dose delivered to the target.  Since the energy loss of the 
proton per unit pathlength was proportional to the inverse square of its energy, 
placing attenuating material upstream from the target substantially reduced the 
proton’s range while retaining most of the energy for deposition within the target 
(106).   
In beam lines that deliver high energy protons, attenuating plates were 
used to coarsely step the proton energy to the desired range, as in the Proton 
Therapy Center – Houston (107) and the Paul Scherrer Institute in Switzerland 
(108).  In beam lines for lower energy protons that treat small superficial legions 
such as ocular tumors, a wedged attenuator was placed in the beam’s path to 
finely degrade the proton’s range to conform to the distal edge of the tumor.  This 
technology was used at several proton facilities including the Hahn-Meitner-
Institut (HMI) in Berlin (109, 110) and at Massachusetts General Hospital (MGH) 
(111, 112)  The latter type of range degrader was built in order to localize the 
92 
 
distal edge of the proton spread out Bragg peak (SOBP) with a high degree of 
precision. 
4.2.2 Preliminary determination of depth variation 
Construction of the external collimation system required some knowledge 
of the magnitude of daily or inter-fractional and intra-fractional beam range 
corrections.  The wedges had to be large and steep enough to correct for the 
majority of anatomic variations and calculation based variations encountered 
during a patient’s fractionated radiotherapy.  To estimate the range of variations 
in actual patient treatment, we measured the distance from the abdomen to 
anterior rectal wall in the mid-sagittal plane near the superior prostate and 
proximal seminal vesicles in patients without rectal balloon immobilization (Figure 
41).  Previous studies indicate that both interfractional and intrafractional 
variation of the target organs was greatest at the level of the seminal vesicles (44, 
61). 
 
Figure 41: Measured depth from the abdomen to the anterior rectal wall 
93 
 
Taking advantage of a previously completed repeat CT imaging research 
protocol, the mean depth was calculated for each patient and subtracted from 
each weekly CT image set for 30 patients and a total of 154 depth variations.  
One standard deviation of variation was 4.5 millimeters (Figure 42).  The total 
range of beam attenuation for our patient set-up device had to  be capable of at 
least 9 millimeters (2 standard deviations) range attenuation both anteriorely and 
posteriorely to correct for anatomic variation in 95% of cases.   Some additional 
margin was added to the nine millimeters to account for potential variation in the 
calculated range. 
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Figure 42: Measured depth variations to the anterior rectal wall 
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 The absolute depth to the anterior rectal wall was also important for 
wedge design.  The mean depth to the anterior rectal wall from the abdomen was 
13.8 centimeters with a standard deviation of 1.5 centimeters.  The maximum 
therapeutic energy of the synchrotron at the PTC was 250 MeV.  After scattering, 
shifting, and monitoring in the nozzle, the maximum range of this energy was 
approximately 28.5 centimeters.  Considering the depth to the target, the wedges 
could be no more than 11-12 centimeters in height. 
4.2.2 Wedge system design 
 The relationship between the wedge dimensions and the total range of 
attenuation was illustrated in Figure 43.  In the wedges’ reference position, the 
total physical thickness of the wedge was the product of the wedge length and 
the tangent of the wedge angle, or the maximum height of the wedge.  The 
distance that the dynamic wedge can travel was limited by the need to maintain a 
uniform thickness across the beam.  Thus, the maximum and minimum depths 
were limited by the length of the wedges and the width of the treatment beam.  
For the case for prostate treatment, we assumed that the width of the beam 
would be approximately 10 centimeters.  The total attenuation range was the 
difference in the length of the wedges and the beam multiplied by the tangent of 
the wedge angle. 
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 Reference Position Maximum Depth Minimum Depth
θ θ θ
θ θ θ
a1 a2 a1 a2 a1 a2a3 a4 a3 a4 a3 a4
Lw Lw Lw
LB LB LB
a1 + a3 = a2+ a4= Lw tan θ a1 = a2+ a4 = 0.5(Lw + LB) tan θ a1 + a2 = a3+ a4 = (1.5Lw – 0.5LB) tan θ
Total Attenuation Range = (1.5Lw – 0.5LB) tan θ − 0.5(Lw + LB) tan θ
= (Lw-LB) tan θ  
Figure 43: Relation of attenuation range to wedge width and angle 
 We selected a wedge angle of 26.5 degrees.  The tangent of this angle 
was one-half.  The physical thickness of the wedges would change by exactly 
one-half the distance the dynamic wedge was moved into or out of the field.  For 
our prototype design, we created 20 centimeter square wedges that were 10 
centimeters in height.  These dimensions allowed for 2.5 centimeter correction in 
either direction.  In hindsight, we should have created these wedges slightly 
smaller.  Additional attenuation added distal edge degradation, additional lateral 
scatter, and generated additional neutrons. 
After determining the dimensions of the dual wedge range shifter, we 
selected an appropriate commercial stepping motor, controller, and mountable 
slide.  The Velmex Bislide (Velmex, Inc., Bloomfield, NY) commercial system fit 
our specifications (Figure 44).  The total travel length of the motor was 10 inches.  
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The motor’s precision was approximately 1/1000”, ensuring that the precision of 
our range shifter would meet our criteria as long as the wedges were well 
constructed.  The screw index was one tenth of an inch per revolution.  The 
stepper motor also included commercial software; however, Labview was used to 
interface the range shifter with the beam detector in our experimental setting for 
future interfacing with our detector from aim 1. 
 
 
Figure 44: Velmex Bislide stepper motor 
We built a custom attachment from the motor carriage of the Velmex 
Bislide to the top wedge (Figure 46).  The bottom wedge was inverted and 
attached to the bottom side of our measurement cart to achieve uniform range 
modulation across the field (Figure 45).  Our measurement cart had a second 
rack below the wedges to place phantoms for measurement. 
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Figure 45: Mobile cart for mounting wedge system 
 
 
Figure 46: Wedge mounted to the carriage of the stepper motor 
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4.2.3 Experimental methods 
The first experiment determined the water equivalent thickness of our dual 
wedge range shifter.  The proton beam was set to 23.5 cm depth.  A TG-51 
single axis water phantom and Markus parallel plate ionization chamber were 
positioned beneath our wedges on our cart rack (Figure 47).  The proton depth 
dose through the distal falloff was measured with the wedges in place (10 cm 
physical thickness) and with the wedges replaced with calibrated solid water 
blocks of 6 cm thickness.  The measured range of the depth dose with the 6 
centimeters of calibrated Lucite build-up material was subtracted by 6 cm to 
determine the range of the beam without any buildup material in place.  The 
difference between this value and the measured range of the beam with the 
wedges in place yielded the total water equivalent thickness of the wedges.  By 
dividing this value by ten centimeters, the total thickness of the wedges, the 
relative water equivalent thickness of the Lucite in our wedges was calculated.  
This value was necessary for calculating the distance to move our motor to 
generate a desired adjustment in depth. 
We then calculated the distance necessary to move the motor to shift the 
proton beam by a calculated -1cm, -5 mm, 5 mm, and 1 cm in depth (greater 
than 2 SD from Figure 42).  These values were twice the desired range 
adjustment due to the angle of the wedge divided by the relative water equivalent 
thickness of our wedges.  After adjusting the proton beam by our calculated 
amounts from our reference position, the depth dose was measured in our 
scanning water phantom.  The depth of R50 was then estimated by linear 
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integration between our measurement points and these depths were compared 
to those predicted by our calculation.  The deviation between the range that we 
calculated and the measured range would generate the error in the range 
correction.  The standard deviation of these errors was an independent source of 
uncertainty for determination of the composite distal margin in aim 3. 
 
Figure 47: Experimental set-up for wedge precision 
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4.3 Results 
4.3.1 Calculation of the RWET of the wedge system 
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Figure 48: Calculation of RWET of wedges from measurements 
 
Figure 48 illustrated the two depth dose curves measured to determine the 
relative water equivalent thickness of the wedges.  The blue series was the depth 
dose with the 6 centimeters of water equivalent material in the beam.  The red 
series was the depth dose with the wedge in the reference position (10 
centimeters physical depth).  The green series was the depth dose with the 6 
centimeters of build-up material that has been shifted by 5.6 centimeters for 
visual reference.  As shown in the figure, the distance to agreement between the 
101 
 
two relations was 5.6 cm resulting in a measured total WET of 11.6 centimeters 
and a RWET of 1.16 when compared to water. 
4.3.2 Wedge precision determination 
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Figure 49: Measured depth dose curves after calculated shifts 
 Figure 49 illustrated the measured depth dose curves after a calculated 
shift of -10, -5, 5, and 10 millimeters.  For each curve, the 50% range was 
estimated by linear interpolation between the data points.  These values were 
then compared with the estimated 50% range on the reference depth dose curve.  
The absolute distance to agreement between the measured 50% range and the 
calculated shifts were shown next to each curve.  Additionally, the calculated 
range shifts were highly correlated with the measured shifts (Figure 50).  The 
standard deviation of the distance to agreement was 0.04 mm. 
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Figure 50: Correlation of calculated and measured depth dose 
4.4 Discussion 
4.4.1 Summary  
 Custom inverted Lucite wedges were designed to degrade the range of 
the proton beam to precisely match the distal edge of the target organs.  The 
dimensions of these wedges balanced attenuation range with size, compatibility 
with proton gantry, proton range limit, wedge cart, and treatment couch.The total 
WET of the wedges was first determined.  Then the distance was calculated to 
adjust the  proton’s range.  This pre-determined shift was a surrogate for the 
detector signal and subsequent depth measurement from our detection device 
discussed in the previous chapter.  One standard deviation of agreement was 
103 
 
0.04 millimeters.  This figure is negligible compared to the in vivo and in vitro 
uncertainties of the detector. 
4.4.2 Study limitations 
 One issue that was not addressed during the testing of our aim was the 
time effect between when the wedges receive a signal and the time that the 
range correction actually occurs.  With the speed of the controller and motor 
along with the screw index, the maximum estimated wedge speed was 1 inch per 
second.  Compared with the patient’s anatomic variation from bladder and rectal 
filling, this speed was more than adequate.  However, breathing induced range 
variation was not considered.  This issue was a limitation of the entire localization 
technique since the distal falloff was only measured and corrected once per spill, 
or approximately every two seconds.  Further investigation of the effects of 
patient breathing on variation of the anatomy in the lower abdomen was needed 
before translating this technique into the clinic.   
There were two potential solutions to correct for breathing induced proton 
range variation.  The first was to use an immobilization device that fits completely 
around the patient’s anatomy.  Another potential solution was the use of 
stereotactic monitoring and localization with a camera system in conjunction with 
our endorectal detector to estimate range variations between pulses.  The ability 
of the wedges to adjust their position relative to a real-time breathing trace from 
the Varian RPM system (Varian Medical Systems, Palo Alto, CA) was tested.  
The lag between the position input and the time when the motor matched the 
position was slightly greater than 100 milliseconds.  However, without 
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corresponding data on the magnitude of breathing-induced depth changes and 
the correlation of those changes with the patient’s skin surface, this potential 
method was speculation. 
Another potential improvement of the system would be to add another 
dimension of proton beam correction.  Additional fibers within the balloon could 
detect variation of the depth along the axis of the balloon.  Based on difference in 
these measured values, a third wedge could be added to rotate the distal edge of 
the beam.  The impact and feasibility of this technique could be simulated in the 
treatment planning system by measuring the rotation of the rectum and target 
organs in CT patient data and drawing custom regions of interest as a surrogate 
for the third wedge.   
4.5 Specific Aim 2 conclusions 
A dual wedge Lucite range degrader was designed with the initial goal of 2 
millimeter precision, and we demonstrated that our design meets and exceeds 
our initial expectations.  Considering the precision of both the detector and the 
wedges, the range shifting portion of the device should not significantly contribute 
to the treatment uncertainty and the residual distal margin needed to ensure 
treatment coverage with our localization technique. 
105 
 
Chapter 5: Dosimetric comparison of IMRT, bilateral proton, and 
single anterior proton beam treatment of the prostate 
5.1 Introduction  
Specific Aim 3: Determine dosimetric benefit of utilizing the in vivo proton 
beam detection device and external proton beam range shifter,  
Working hypothesis: Using the measured precision of the in vivo proton beam 
detection device and external proton beam range shifter, the reduced margin 
planning treatment strategies reduce mean rectal dose by 20% over conventional 
bilateral proton and IMRT photon therapies. 
The conversion of proton stopping power ratio from CT Hounsfield units to 
calculate proton range carries large uncertainties, necessitating large distal 
margins to ensure target coverage and diminishing the major benefit of proton 
therapy.  In the case of proton radiotherapy for prostate cancer, the major dose-
limiting organ is the rectum, which is adjacent to the prostate target. In current 
practice, institutions adopt bilateral treatment proton beams to avoid pointing the 
sharp falloff of the Bragg peak directly in front of the rectum. Unfortunately, this 
beam arrangement introduces higher rectal dose due to the large lateral 
penumbra of the proton beam.  Several published studies compare bilateral 
proton treatment with photon IMRT of the prostate and reported significant 
sparing of the rectum and bladder volume at low doses (113-116).  While low 
dose sparing of normal tissues is still beneficial to prostate cancer patients, these 
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improvements may have minimal effect on acute rectal and bladder toxicity and 
may not allow target dose escalation or hypofractionation of treatment. 
Methods to detect the anterior beam at depth were developed at this 
institution (this thesis) and elsewhere (99, 100) to eliminate the large distal proton 
planning margin, enabling abrupt dose falloff at the anterior rectal wall rather than 
the relatively shallow falloff of the lateral beam penumbra with conventional bi-
lateral treatments. 
The purpose of this chapter is to evaluate the ability of an anterior proton 
beam to adequately spare the rectum considering the measured precision of our 
in vivo patient set-up technique discussed thus far in the thesis.  this treatment 
technique will be compared with the conventional treatment planning techniques: 
eight-field IMRT and bilateral proton treatment of the prostate.  Based on the 
estimated rectal dose for patients receiving our technique for their proton 
radiotherapy, the thesis hypothesis will be evaluated. 
5.2 Materials and methods  
5.2.1 Patient protocol 
The first twenty-seven prostate cancer patients treated with proton therapy 
at this institution enrolled in an IRB-approved prospective treatment planning 
study to compare standard IMRT and bi-lateral proton treatments with a single 
anterior proton beam treatment.  An additional treatment plan was generated to 
simulate patient treatment with an anterior proton beam with a reduced distal 
margin.  All twenty-seven patients had localized cancer of the prostate (T1-T3, 
N0, M0) prescribed to 75.6 CGE in 42 treatment fractions.  Patients were 
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immobilized with the Dual Leg Positioner (Cisco Systems, San Jose, CA) and 
marked with external skin fiducials for treatment alignment with the in-room 
lasers.  All patients were instructed to maintain a full bladder and empty bowel.  
Endorectal balloons (MEDRAD, Inc., Pittsburgh, PA) were inserted into each 
patient’s rectum to provide additional prostate immobilization, expand the rectal 
volume, and push the upper bowel out of the treatment field.  A single CT data 
set was created for each patient, contoured by a single physician (AKL), and 
exported into treatment planning systems for plan generation.  The rectum was 
contoured from the anus to the recto-sigmoid flexure.  The rectal wall was 
generated by contracting the rectal contour by 3 mm and generating an ROI 
between the rectal contour and contracted contour.  The bladder wall was 
generated identically to the rectal wall. 
5.2.2 Treatment planning 
 For the patients’ proton radiotherapy treatment, reference CT data sets 
were imported into Varian’s Eclipse treatment planning system.  Each daily 
fraction was delivered with equally weighted parallel-opposing passively 
scattered proton beams as illustrated in the middle of Figure 51.  Bilateral proton 
beam treatment margins were generated with our standard institutional margin 
recipes. The lateral aperture margins for both the bilateral treatment plans and 
anterior proton beam treatment plans included allowances for set-up uncertainty 
(2mm), patient motion (3mm), and proton lateral beam penumbra (12 mm) for a 
total of 17 mm.  The distal and proximal margins accounted for uncertainties in 
converted CT Hounsfield units to proton stopping power.   For the bilateral plans, 
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generation of these margins included 3.5% of the proton depth plus a 3 mm 
machine-dependent beam energy uncertainty for a total of 10-13 mm distally and 
8-10 mm proximally.  The distal margin for the anterior proton beam treatment 
was 2 mm to account for the estimated precision of the in vivo proton beam 
detection method we discussed in the previous two chapters. By measuring the 
beam at depth, we avoid the 3.5% of the depth distal margin because we have 
not calculated the beam pathlength from CT Hounsfield units.  Since we detect 
the beam during each proton spill, we also avoid set-up and interfractional motion 
uncertainties.  The proximal margins of the anterior proton beam plans were also 
set to 2 millimeters.  The compensator smearing corrected for movement of 
tissue heterogeneities in the beam path by assuming the water equivalent depth 
to the distal edge of the target at any point is the maximum of its neighbors within 
the smearing radius.  Determination of the smearing radius included the square 
root of the square of 3% of the target depth added with the square of set-up and 
motion uncertainties for a total of 8-10 mm.  The smearing margin for the anterior 
beam plans was maintained at 7 mm. 
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Figure 51: A dosimetric comparison between IMRT, bilateral proton therapy, 
and anterior beam proton therapy 
CT data was imported into Phillip’s Pinnacle treatment planning software 
for IMRT treatment planning generation.  The IMRT PTV included an 8 mm 
isotropic expansion of the prostate except along the posterior border which was 5 
mm (Figure 51: Left).  The prescription dose was 75.6 CGE (shown in red).   The 
IMRT treatment plans were optimized to spare normal tissue dose in the rectum 
and bladder at dose levels of 70, 60, and 40 Gy.  Additional constraints were set 
to prevent hotspots in the femoral head and general normal tissue.  The dose to 
the CTV was normalized to 100% coverage on the IMRT and bilateral treatment 
plans.  In some case, complete coverage of the CTV was challenging with a 2 
mm margin anterior plan due to the approximation of the compensator before 
accounting for scatter.  In these cases, the compensator was manually modified 
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and the treatment prescription set to a comparable level as the bilateral proton 
plans. 
Additionally, we generated anterior proton plans with varying distal 
margins on a single patient to evaluate the effectiveness of treatment is our in 
vivo beam detection is more precise (down to 0 mm margin) or less precise ( as 
much as 5 mm margin) than we originally anticipated.  With the known 
relationship of distal margin to mean dose to the rectum, the treatment planning 
results (2 mm margin) can be extrapolated to the anterior treatment with a margin 
reflecting the measured precision of our device (2.4 mm). 
5.2.3 Data analysis 
 Each patient’s dose volume histograms for the prostate, proximal seminal 
vesicles, rectum, bladder, rectal wall, and bladder wall were collated in MATLAB 
and exported to Excel for data analysis.  A single dose population histogram was 
generated for each organ in each treatment arm to illustrate the average relative 
volume exposed to a dose level.  The terms Grey and cobalt-grey-equivalent 
were used interchangeably in this study.  The relative biological value used for 
clinical proton treatment at our institution was 1.1.   The dose levels were 
generated in 10 cGy bins for display in the dose population histograms.  For each 
patient and organ, the maximum dose, mean dose, and median dose was 
recorded.  For the prostate and proximal seminal vesicles, the minimum dose to 
0.1 cc was recorded as well.  The average, standard deviation, minimum, and 
maximum of each of those dose metrics was summarized in tabular form.  To 
statistically compare our treatment arms for each organ, p-values were 
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generated with the student t-test for each dose bin between each treatment arm 
for each critical organ.  These results were displayed graphically relating the 
probability of any treatment arm pairing to be statistically the same at each dose 
bin.  These graphs were called P-plots. 
5.3 Results 
5.3.1 Target organ coverage 
 Table 2 summarizes the dosimetric statistics for the prostate and the 
proximal seminal vesicles across our entire 27 patient group.  Volume, mean 
dose, median dose, maximum dose, and minimum dose are displayed for each 
treatment arm and organ of interest.  For each metric the statistical mean, 
standard deviation, minimum, and maximum describing the 27 patients were 
generated.  Prostate coverage was comparable between the three treatment 
arms.  Scatter from the pubic symphysis resulted in small hot spots in the middle 
of the prostate for some patients.  A single statistical outlier had a maximum 
hotspot of 87.3 CGE which was reflected in the mean hot spot over the 27 
patients (81.1 CGE for Anterior proton versus 80.3 CGE for IMRT and 79.3 CGE 
for bilateral proton treatments). The anterior proton plan appears more 
heterogeneous, however many clinicians feel that the relative hot and cold spots 
on proton plans in general average over a fractionated treatment due to the 
sensitivity of the dose distribution to registration errors of heterogeneities in the 
beam path.  The invariance of the dose distribution assumed in photon treatment 
does not apply for proton treatments. 
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Average 1SD Max Min
Prostate Total Volume (cc) 66 18 108 38
IMRT Max Dose (0.1cc) 80.3 1.0 82.8 78.9
Mean Dose 78.5 0.5 80.0 77.6
Min Dose (0.1cc) 76.7 0.4 77.6 76.0
Median Dose 78.5 0.5 80.0 77.6
Bilateral Max Dose (0.1cc) 79.3 0.5 80.6 78.1
Mean Dose 77.9 0.3 78.7 77.2
Min Dose (0.1cc) 76.5 0.3 77.2 76.1
Median Dose 77.8 0.3 78.7 77.1
AP Max Dose (0.1cc) 80.9 1.1 83.3 79.4
Mean Dose 77.9 0.4 78.7 76.6
Min Dose (0.1cc) 75.4 0.5 76.4 74.1
Median Dose 77.8 0.5 78.7 76.6
Proximal SV Total Volume (cc) 8 3 15 2
IMRT Max Dose (0.1cc) 79.8 0.8 81.7 78.6
Mean Dose 78.5 0.5 79.9 77.5
Min Dose (0.1cc) 77.1 0.5 77.9 76.1
Median Dose 78.4 0.5 79.9 77.5
Bilateral Max Dose (0.1cc) 78.5 0.5 79.7 77.6
Mean Dose 77.6 0.5 78.7 77.0
Min Dose (0.1cc) 76.8 0.5 78.0 76.1
Median Dose 77.6 0.5 78.7 76.7
AP Max Dose (0.1cc) 79.7 0.9 81.5 77.9
Mean Dose 77.9 0.6 79.5 76.8
Min Dose (0.1cc) 76.0 1.4 78.2 70.6
Median Dose 77.8 0.6 79.4 76.8  
Table 2: Dose statistics of the prostate and proximal seminal vesicles 
 The dose population histograms of the prostate are shown in figure 52.  
The IMRT treatment plans appear to be slightly hotter than the bilateral proton 
treatment plans; however, these two treatment techniques were both normalized 
to receive full treatment coverage to the CTV.  The dose population histogram for 
the AP proton beam appears troubling at first glance.  The Eclipse treatment 
planning system had difficulty covering the CTV with a 2 millimeter distal margin 
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treatment planning technique.  This is because calculation of the range and 
subsequent range compensator generation is made without considering lateral 
scatter of the proton beam.  After the full dose calculation is performed, the 
effective treatment margin at any one point along the distal edge of the treatment 
beam is slightly different from the margin set by the user.  This is an inherent 
weakness of the treatment planning system rather than an indictment of the 
treatment planning strategy.  Some compensation for this miscalculation was 
made by manual editing the range compensator and increasing the prescription 
isodose line. 
Prostate Dose Population Histograms for 27 Patients
Dose (Gy)  
Figure 52:  Dose population histogram of the prostate 
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Figure 53: Dose population histogram of the proximal seminal vesicles 
 Figure 53 illustrates the dose population histograms of the proximal 
seminal vesicles for our three treatment arms.   The results are similar to those 
for the prostate.  The mean patient minimum dose to the seminal vesicles was 76 
CGE which is slightly better than the 75.4 CGE for the prostate.  The dose to the 
proximal seminal vesicles with our anterior proton treatment plan was slightly 
more heterogeneous than the other two arms. 
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5.3.2 Rectum and rectal wall dose 
Average 1SD Max Min
Rectum Total Volume (cc) 156 17 196 130
IMRT Max Dose (0.1cc) 80.1 0.9 82.0 78.3
Mean Dose 31.5 4.2 38.8 22.3
Median Dose 26.5 4.5 37.7 15.6
Bilateral Max Dose (0.1cc) 78.5 0.7 80.3 77.1
Mean Dose 23.3 3.8 29.9 16.9
Median Dose 7.9 5.1 19.4 0.6
AP Max Dose (0.1cc) 79.3 1.1 83.0 77.5
Mean Dose 10.5 2.3 15.7 6.9
Median Dose 0.0 0.0 0.1 0.0
Rectal Wall Total Volume (cc) 31 4 38 26
IMRT Max Dose (0.1cc) 80.0 0.9 81.9 78.2
Mean Dose 33.3 3.6 38.3 26.4
Median Dose 23.4 3.6 31.7 15.1
Bilateral Max Dose (0.1cc) 78.5 0.7 80.2 77.1
Mean Dose 24.6 2.9 29.7 19.8
Median Dose 3.8 2.7 10.7 0.4
AP Max Dose (0.1cc) 79.1 1.2 84.1 77.3
Mean Dose 16.2 2.3 21.7 12.3
Median Dose 0.0 0.0 0.0 0.0  
Table 3: Dose statistics of the rectum and rectal wall 
 Differences in dose to the rectum and the rectal wall were substantial 
between our treatment groups (Table 3).  Mean dose to the rectum and rectal 
wall was greatest in the IMRT group (31.5 and 33.3 CGE) followed by the 
bilateral proton group (23.3 and 24.6 CGE) and anterior proton group (16.2 CGE).  
Maximum dose was similar between treatment groups.  Over half the rectum was 
spared in our anterior treatment group (0 CGE) and nearly half in the bilateral 
group (median dose of 3.75 CGE). 
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Figure 54: Dose population histograms of the rectal wall and rectum 
Figure 54 illustrates the dose population histograms for the rectum 
(bottom) and rectal wall (top) for our three treatment techniques.  The rectal 
sparing is nearly equivalent between bilateral and IMRT treatments except for 
low dose regions (sub-30 CGE) where protons substantially outperform IMRT for 
both the rectum and the rectal wall.  The anterior treatment achieves nearly 
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approximately 10-15% sparing of the rectal wall by volume of conventional 
bilateral proton treatment at all dose levels.  The dose delivered to the entire 
rectum with the anterior proton beam treatment is much less than the bilateral 
and IMRT treatment techniques at all dose level less than 70 CGE.  The dose to 
the rectum is comparable between the IMRT and bilateral proton arms for doses 
greater than 40 CGE.  The dose to the rectum with the anterior beam planning is 
nearly half the dose from the other two treatment arms.  
The p-plots provide a visual representation of the statistical significance 
between the treatment arms (Figure 55).  The dose population histograms 
display error bars illustrating the standard deviation of the data sets at each dose 
bin.  The standard deviation of the mean (SDM), which is used for determining 
the statistical significance, is the standard deviation divided by the square root of 
the number of patients.  Therefore the SDM is greater than a factor of 5 times 
smaller than the standard deviation.  In Figure 54, the SDM is extremely small.  
Therefore, small dosimetric changes between the treatment groups can change 
the statistical significance abruptly.  The abrupt changes of the statistical 
significance are represented by the steep gradients of the p-plots.  Figure 55 
summarizes the statistical differences between our treatment arms for rectal 
sparing.  The rectal dose for anterior treatment plan is significantly less then 
IMRT (red) for all dose level less then 80 CGE (p< 0.01) and less than bilateral 
proton for all dose levels less than 77.5 CGE (p < 0.01). The bilateral proton plan 
treats significantly less rectum then the IMRT plan for dose levels less than 35.5 
CGE and significantly more rectum from 46.7 CGE to 71.4 CGE (p<0.01).   The 
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bilateral proton and IMRT plans are nearly equivalent at doses near prescription 
levels. 
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Figure 55: P-plot of the rectum 
 The statistical differences in the volume of rectal wall treated by our 
treatment arms are summarized in figure 56.  As in the case of the rectal volume, 
the anterior treatment plan treated less rectal wall than the IMRT plan for all dose 
levels and less than the bilateral proton plan for all dose levels less then 77.4 
CGE (p < 0.01).  The bilateral proton plan treated less rectal wall than the IMRT 
for dose levels less than 41.4 CGE and greater than 73.3 CGE (p < 0.01). 
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Figure 56: P-plot of the rectal wall for all three treatment techniques 
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5.3.3 Bladder and bladder wall dose 
Average 1SD Max Min
Bladder Total Volume (cc) 335 141 620 133
IMRT Max Dose (0.1cc) 80.0 0.9 82.0 78.1
Mean Dose 19.0 6.4 33.1 8.8
Median Dose 8.0 6.7 24.6 1.9
Bilateral Max Dose (0.1cc) 78.7 0.6 79.9 77.6
Mean Dose 14.7 5.7 31.2 7.5
Median Dose 1.2 4.2 21.8 0.0
AP Max Dose (0.1cc) 80.1 1.2 82.9 77.2
Mean Dose 22.1 9.4 43.4 8.8
Median Dose 8.9 16.8 58.9 0.0
Bladder Wall Total Volume (cc) 57 18 94 28
IMRT Max Dose (0.1cc) 79.8 0.9 81.9 78.1
Mean Dose 19.8 6.0 33.4 10.2
Median Dose 7.4 6.5 25.0 1.7
Bilateral Max Dose (0.1cc) 78.7 0.6 79.9 77.6
Mean Dose 16.6 5.4 30.5 8.8
Median Dose 0.8 3.0 15.6 0.0
AP Max Dose (0.1cc) 80.1 1.2 82.8 77.7
Mean Dose 22.7 8.7 40.1 9.6
Median Dose 7.8 15.1 50.6 0.0  
 
Table 4: Dose Statistics of the Bladder 
 Dose to the bladder wall were nearly opposite of the rectal wall dose 
results (Table 4).  The mean dose to the bladder and bladder wall was greatest in 
the anterior proton group (22.1 and 22.7 CGE) followed by IMRT group (19.0 and 
19.8 CGE) and bilateral proton group (14.7 and 16.6 CGE).  The maximum dose 
to the bladder and bladder wall were comparable between the IMRT and anterior 
proton beam plans and slightly reduced in the bilateral proton beam plans.  The 
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median dose to the bladder was greater in the anterior treatments than the other 
two treatment arms. 
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Figure 57: Dose population histograms of the bladder and the bladder wall.   
 Figure 57 shows the dosimetric comparison of the three treatment 
techniques for bladder and bladder sparing.  The ability of the bilateral proton 
and IMRT plans to spare the bladder is comparable at dose levels greater than 
30 CGE.  The bilateral plan is slightly better for the low dose regions of the 
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bladder and bladder wall.  The anterior proton plan delivers approximately 10% 
more dose to the bladder wall than IMRT for dose levels greater than 30 Gy and 
at all dose levels when compared to bilateral proton treatment. 
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Figure 58: P-plot of the bladder wall dose 
 The statistical differences in the volume of bladder wall treated with our 
three treatment technique are summarized in figure 58.  The IMRT plan delivered 
more dose to the bladder wall than the anterior proton technique for doses less 
than 7.8 CGE and less dose from 19.6 to 73.2 CGE (p<0.01).  The IMRT plan 
delivered more dose to the bladder wall than the bilateral proton technique for 
doses less than 31.9 CGE and less dose from 39.8 to 74.1 CGE (p<0.01).  The 
anterior proton technique treated more bladder wall than the bilateral technique 
for all dose levels less than 77.5 CGE (p<0.01). 
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Figure 59: P-plot of the bladder 
 The statistical differences in the volume of bladder treated with our three 
treatment technique are summarized in figure 59.  The IMRT plan delivered more 
dose to the bladder wall than the anterior proton technique for doses less than 
6.7 CGE and less dose from 22.8 to 74.9 CGE (p<0.01).  The IMRT plan 
delivered more dose to the bladder wall than the bilateral proton technique for 
doses less than 38.4 CGE and more volume at levels greater ant 73.5 CGE 
(p<0.01).  The anterior proton technique treated more bladder wall than the 
bilateral technique for all dose levels (p<0.01). 
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4.3.4 Femoral head dose 
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Figure 60: Dose population histogram of the femoral heads 
 Figure 60 illustrates that femoral head dose is considerably more for 
bilateral proton treatment than for standard 8-field IMRT.  The mean dose to the 
femoral heads with the bilateral treatment techniques was 25.1 CGE and 17 CGE 
for the IMRT.  However, the patient average maximum dose to 0.1 cc of the 
femoral heads was 34.5 CGE for the bilateral proton technique and 41.4 CGE for 
the IMRT treatments.  Generally the femoral heads are constrained to a 
maximum dose of approximately 45 CGE, so IMRT treatment may be more likely 
to illicit morbidity than the bilateral treatment.  Anterior beam treatment delivers 
nearly zero dose to the femoral heads. 
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5.3.5 Rectal dose and distal margin 
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Figure 61: Rectal dose volume histogram as a function of distal margin 
 Figure 61 illustrates the dose volume histograms (DVH) of the prostate 
and rectal volume for a single patient calculated from a two field conventional bi-
lateral proton beam plan and a single anterior proton beam plan with distal 
margins of 0 to 5 mm.  The mean rectal dose is also displayed for each treatment 
planning strategy.  The mean rectal dose scales linearly with increasing distal 
margin, approximately 100 cGy per millimeter.  Although our predicted distal 
margin is 2.4 millimeters and our dosimetric study tested a 2 millimeter margins, 
we can realistically predict that the mean rectal dose over the 27 patients should 
be no more than 100 cGy higher with a 2.4 mm distal margin.  Also, this figure 
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suggests that the rectal sparing capability of the anterior beam treatment is 
preserved even with a 5 mm margin.  Table 5 presents the data from Figure 61 in 
tabular form.  The mean dose, V40, V60, and V70 are displayed for the bilateral 
proton and anterior proton plans.  For comparison, the values for the anterior 
plans were normalized to those of the bilateral plans.  The table indicates that the 
values of V60 and V70 are more sensitive to the size of the anterior treatment 
margin with comparing anterior treatment with bilateral treatment. 
Mean Dose  V40 V60 V70
[cGy] % Bilateral % Vol % Bilateral % Vol % Bilateral % Vol % Bilateral
AP 0mm 481.5 0.25 5.26 0.24 2.75 0.21 1.39 0.19
AP1mm 581.1 0.30 6.54 0.29 3.76 0.29 2.11 0.29
AP2mm 690.1 0.36 7.97 0.36 4.83 0.37 3.01 0.41
AP3mm 798.5 0.42 9.36 0.42 5.98 0.46 3.93 0.54
AP4mm 921.1 0.48 10.91 0.49 7.30 0.56 4.99 0.68
AP5mm 1058.4 0.55 12.64 0.57 8.74 0.67 6.28 0.86
Bilateral 1912.4 1.00 22.33 1.00 13.10 1.00 7.29 1.00  
Table 5: Table of rectal dose as a function of anterior proton beam margin 
size 
5.4 Discussion 
5.4.1 Summary 
In this chapter, we set out to compare the dosimetric impact of IMRT and 
passively scattered bilateral proton beam treatment and investigate the utility of 
anterior beam proton treatment utilizing the proton’s rapid distal fall-off for optimal 
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rectal sparing.  The previous two chapter outlined methods to detect the anterior 
beam at depth.  These methods eliminated the distal proton planning margin, 
enabling abrupt dose falloff at the anterior rectal wall rather than the shallow 
falloff of the lateral beam penumbra with bi-lateral treatments.  
The first 27 prostate cancer patients treated with protons at this institution 
enrolled in a prospective treatment planning study to compare the three 
treatment techniques.  Based on the measured precision in the previous two 
chapters, we estimated that we needed a 2.4 millimeter treatment planning 
margin to ensure treatment coverage.  We relaxed our 95% confidence criteria to 
90% and applied a 2 mm distal margin for anterior proton beam planning based 
on our initial hypothesis.  The anterior beam treatment significantly spared the 
rectum and anterior rectal wall more than the IMRT and bilateral beam 
treatments at all dose levels.  However, bladder and bladder wall dose was 
greater in the anterior beam treatment than IMRT and bilateral beam treatments 
nearly all dose levels.  No dose was delivered to the femoral heads with the 
anterior beam treatment while the IMRT and bilateral proton treatments delivered 
a mean dose of 17.0 CGE and 25.1 CGE to the femoral heads respectively. 
5.4.2 Study limitations 
 Delivery of a highly conformal proton treatment plan with the Eclipse 
treatment planning system was challenging because of approximations made 
during the generation of the range compensator.  Varian upgraded their software 
once during this experiment, and the resulting anterior proton plans were 
noticeably more homogeneous with the updated software.  When the user set a 
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particular margin for the target organs, the distance of the prescription isodose to 
the target organ should be close to this value at all points along the distal target.  
However, the residual distance between the target and prescription isodose did 
not always match the specified distal margin.  Although the CTV was not always 
100 % covered by the anterior plan, the normal tissue dose could potentially be 
lower with improved software.  The TPS generated cold spots were compensated 
by increasing the dose delivered to the tumors, which in turn generated many 
hotspots.  The compensator was manually edited in problematic areas, greatly 
increasing the range of the beam in nearby areas where additional margin was 
not necessarily needed. 
5.4.3 Previous dosimetric comparisons 
 Several authors have investigated the potential of proton therapy relative 
to IMRT with dosimetric planning studies.  Lomax (113) compared proton and 
photon intensity modulated radiotherapy in nine different patients with a variety of 
treatment legions including one patient with metastasizing prostate carcinoma 
treated with a single anterior spot-scanning proton beam.  All plans included 
planning target margins as indicated in ICRU 50 and additional corrections were 
made for tissue inhomogeneities in the beam path.  They reported greater 
treatment homogeneity in the target volume and nearly a three-fold reduction in 
the volume of normal tissue at 30% of the prescription for anterior proton 
treatment over 4-field conformal photon and 9-field IMRT.  Dmean and V50% were 
less for proton treatment over conformal photon and IMRT for all organs at risk; 
however maximum dose and V70% were comparable between proton treatment 
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and IMRT.  Interestingly, rectum was not included as an organ-at-risk for this 
patient.  Since this particular study treated to a relatively large fraction of the 
pelvis when compared with our treatment target, it was difficult to draw 
comparisons between the results. 
 Cella et al (117) compared 3D conformal photon, bilateral proton, 5 field 
IMRT, and 5 field IMPT treatments for a single patient.  The PTV margin was a 1 
cm expansion of the prostate and SV except at the rectal interface where the 
margin was 6 mm.  Both proton arms exhibited increased homogeneity in the 
target and subsequently greater estimated TCP (95% versus 93%).  Rectal 
sparing was increased at all dose levels below V80% by the proton treatments.  
Authors estimated NTCP for late grade-three rectal toxicity with dose escalation 
to 99 Gy to be 4.7% for IMRT and 3.9% for IMPT.  This study used geometric 
margins for their proton plans which resulted in a much more conformal 
treatment plan.  Therefore the comparison with their intensity-modulated proton 
plan was not very useful.  Their bilateral proton plan was comparable to our own 
since our lateral margins are set with a geometric expansion.  After rescaling 
their dose volume histogram, the rectal dose on their patient was comparable to 
our dose population histogram.  However, their IMRT results were extremely 
different.  They excluded the anterior rectum from the PTV, resulting in nearly no 
volume of the rectum receiving dose in excess of 90% prescription.  Their IMRT 
plan also appeared less conformal to the rectum at moderate dose levels (~ 50% 
prescription), and the bilateral consequently spares much more of the rectum 
than predicted in our study. 
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Mock et al (114) compared bilateral proton, 4-field conformal photon, and 
7 field IMRT treatments for 5 prostate cancer patients simulating different 
disease stages by including no SV, proximal SV, or entire SV in the treatment 
volume.  The PTV was generated with a uniform 5 mm expansion of the CTV.  
Inclusion or exclusion of the SV made little difference in the relative dosimetry 
between the treatment arms.  Proton treatment substantially decreased integral 
dose at the cost of decreased dose homogeneity in the PTV.  Proton treatment 
provide near equivalent femoral head sparing to IMRT, slightly increased bladder 
sparing, and substantially increased sparing to the rectal wall (~ absolute 
reduction of 20% at V50% and 10% at V90%).  This study’s methods were closer to 
our own study.  The 5 millimeter clinical target volume expansion they utilized 
was comparable to our lateral margin; however their IMRT plans spared the 
rectum considerably less than in our study.  Their rectal DVH for the bilateral 
proton plans were very similar to our own. 
 Muzik et al (118) compared static and dynamic MLC linac-based IMRT, 
helical tomotherapy , and spot-scanning proton therapy (2 lateral-oblique beams)  
for a single deep seated prostate case.  Again, their rectal dose for their proton 
treatment was similar, but their photon therapy rectal doses were considerably 
higher than our own. 
 Trofimov et al (115) compared IMRT, bilateral proton therapy, and IMPT 
for 10 prostate cancer patients.  They included compensator smearing in addition 
to the traditional planning treatment margins for the target organs.  Comparison 
of their IMRT and bilateral treatment arms was similar to our own results.  They 
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found little difference between the two treatment techniques for all doses in 
excess of 40 Gy.  Their bladder dose results were also similar to our study.  They 
found that the bladder dose in the bilateral proton arm was slightly higher on 
average from 40 Gy to prescription dose than in the IMRT arm and less at low 
doses. 
 Vargas et al (116) reported the rectal and bladder doses of the first 10 
sequentially treated proton cancer patients at their institution.  They set a 5mm 
axial PTV expansion and an 8 mm expansion cranial-caudally.  They optimized 
the proton beam angles to maximally spare the rectum and bladder.  They also 
reduced the lateral aperture margin from 1 cm to 7-8 mm posteriorely.  The 
optimization in beam angle along with the reduction in the lateral aperture at the 
rectum led to significantly more rectal sparing than in our study. 
5.4.4 Bladder and rectal toxicity 
The use of the anterior proton therapy beam for prostate treatment has 
some potential limitations as well.  The most obvious limitation is the increased 
bladder dose.  A series of studies at our institution have modeled GU and GI 
toxicity as functions of bladder and rectal dose respectively (75, 78, 119).  
Results of these studies suggested that the strongest determinant of late bladder 
toxicity was the dose to the hottest 2.9% of the bladder.  The determinants of late 
rectal bleeding were uncertain, however, the rectum did appear to exhibit a 
strong dose-volume effect.  These two results in combination suggested a 
therapeutic gain by reducing the rectal dose-volume at the cost of some bladder 
dose. However, these studies enrolled 3D-CRT patients without the use of a 
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rectal balloon and therefore may not adequately predict the occurrence and GU 
and GI toxicity in highly conformal therapy utilizing rectal balloons which can 
dramatically alter rectal dose(120-122).  Oncologists will have to use their own 
discretion when choosing suitable treatment planning strategies until additional 
investigations addressing GU and GI toxicity in proton therapy prostate patients 
with rectal balloons are published.  
5.4.5 RBE enhancement in the SOBP 
Protons have comparable treatment effect as photons; however, a slight 
adjustment to the prescription is necessary to account for the slight difference in 
the relative biological effectiveness (RBE) of protons relative to equivalent photon 
dose.   The dose delivered with proton treatment must be corrected with the 
experimentally determined RBE and which will convert dose delivered in Gray to 
cobalt grey equivalent (CGE) dose.   The generally accepted value for the RBE 
of protons in the clinical therapeutic range is 1.1, however there is some 
uncertainty in this experimentally determined value, particularly at the distal edge 
of a proton SOBP (123).  In vivo measurement estimates this enhancement at 
approximately 10%. In vitro studies have estimated distal RBE as great as 
1.4.(124)   RBE enhancement at the rectal wall could be problematic; however, 
there is a simultaneous dose fall-off in this region as the intensity of the proton 
beam drops off. Depending on the safety margin used in our in vivo feedback 
system, it is unclear which factor (RBE enhancement vs. rapid dose falloff) will be 
the dominant factor for the rectal wall. Nevertheless, this 1-2 cm dose 
enhancement region would benefit for prostate treatment. Biopsy studies have 
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shown that tumor foci are preferentially located in the peripheral zone of the 
prostate. (125, 126)  The potential biological dose enhancement would improve 
the therapeutic ratio for proton therapy with an anterior beam arrangement.  
5.5 Specific Aim 3 conclusions 
In this chapter, the dosimetric benefit of utilizing the in vivo proton beam 
detection device and external proton beam range shifter was determined 
considering our previous estimation of the technique precision.  The estimated 
precision from the previous two chapters was 2.4 millimeters.  We compared 
treatment with a 2 millimeter anterior proton beam with conventional IMRT and 
bilateral proton treatments for 90% treatment confidence.  Bladder and rectal 
dose are similar between current IMRT and bilateral proton prostate treatments 
at dose levels above 30-40 CGE.  With the implementation of in vivo proton 
beam detection, anterior proton beam treatment of prostate is a possible 
treatment alternative, substantial sparing dose to the rectum and femoral heads 
at the cost of increasing bladder dose.  Given the relative amount of sparing of 
the rectum and increased bladder dose, we anticipate a therapeutic gain with our 
technique. 
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Chapter 6: Dissertation conclusion 
 At the beginning of this thesis, we hypothesized that the use of in vivo 
proton beam detection within a rectal balloon and dynamic range modulation of 
an anterior proton beam will enable the use of a reduced distal margin, reducing 
the mean rectal dose by 20% over conventional bilateral proton treatment and 
IMRT.  To test this hypothesis a scintillation fluid filled endorectal balloon was 
designed for real-time determination of an anterior proton beam’s range.  The 
goal of 2 millimeter precision was nearly met.  The estimated 95% confidence 
interval was 2.4 millimeters.   A dual wedge Lucite range degrader was designed 
with an initial aim of 2 millimeter precision, and the design performance 
exceeded our expectations with an estimated 0.04 millimeter precision.  The 
dosimetric benefit of utilizing the in vivo proton beam detection device and 
external proton beam range shifter was then determined by comparing treatment 
with a 2 millimeter anterior proton beam with conventional IMRT and bilateral 
proton treatments.  The anterior beam treatment exceeded the expectations of 
our hypothesis, halving the dose the rectum receives during treatment.  With the 
implementation of in vivo proton beam detection, anterior proton beam treatment 
of prostate is a feasible treatment option, substantial sparing dose to the rectum.  
Further work to translate this technology into clinical use should be promptly 
completed to reduce incidence of rectal morbidity in patients treated for prostate 
cancer with radiation therapy. 
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